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Background:  Delirium is a severe neuropsychiatric syndrome of brain dysfunction 
precipitated by acute illness and characterised by acute and fluctuating inattention 
and other cognitive and perceptual deficits.  Delirium is common, distressing and 
associated with poor outcomes.  Previous studies examining the impact of delirium 
on cognitive trajectories have been limited by incomplete ascertainment of baseline 
cognition or a lack of prospective delirium assessments.     
The DECIDE study aimed to explore the association between delirium and cognitive 
function over time in participants in an existing population-based cohort aged 65 
years and older with known baseline cognition. 
Methods:  Over a 12-month period, surviving participants from the Cognitive Function 
and Ageing Study II-Newcastle were screened for delirium on admission to hospital. 
Baseline characteristics along with disease relevant clinical parameters were 
recorded. The progression/resolution of delirium was monitored. In those with and 
without delirium, cognitive decline and dementia was assessed at one-year follow-up.  
The effect of delirium on cognitive function over time was evaluated, independent of 
baseline cognition and illness severity, along with the predictive value of clinical 
parameters. 
Results:  82 of 205 participants developed delirium in hospital during the study period 
(40%).  18 of the 135 participants completing one-year follow-up interviews received 
a new diagnosis of dementia. Delirium was associated with an increased risk of new 
dementia diagnosis at follow up, independent of illness severity and baseline 
cognition (OR 8.76 [CI: 1.85 – 41.37], p=0.006).  More than 5 days of delirium and 
more severe delirium were independently associated with worse cognitive outcomes. 
Conclusions:  An episode of delirium whilst in hospital significantly increases risk of 
future cognitive decline and dementia, independent of illness severity and baseline 
cognition.  Given that delirium has been shown to be preventable in around a third of 
cases, it can be proposed that delirium is a potentially modifiable risk factor for 
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1.1 Introduction 
Delirium is a sudden onset cognitive impairment characterised by fluctuating 
inattention and deranged level of arousal precipitated by acute illness.  Delirium is 
common, affecting at least one in five adults in hospital (Ryan et al., 2013).  As well 
as causing considerable patient and carer distress (Partridge et al., 2013), delirium 
results in excess treatment costs of an additional £13,000 per hospitalisation 
(Akunne et al., 2012) and is independently associated with poor outcomes including 
mortality (Witlox et al., 2010).   
Despite the considerable patient and population impact of delirium, it remains under-
researched, with few high-quality studies published, and the impact of delirium on 
cognitive outcomes is relatively unknown.  This chapter outlines how we define and 
diagnose delirium and provides an overview of the epidemiology of delirium, with a 
focus on cognitive outcomes after delirium.  The limitations of current literature and 
the challenges involved with case ascertainment will be discussed and the potential 
for an observational longitudinal study to address key questions on the population 
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1.2 Case study 
Mrs Smith is an 85-year-old lady who lives alone in a two-storey house in the centre 
of Newcastle.  She has lived in the city all of her life and has lots of family and friends 
who live nearby and visit regularly.  One Thursday afternoon, she trips and falls in 
Marks and Spencer.  She immediately has pain in her left hip and cannot move.  An 
ambulance transfers her to the accident and emergency department of her local 
hospital.  Her X-rays reveal that she has broken her hip and will require an operation 
to replace the hip.  She is admitted to the orthopaedic ward and has her operation 
the following day.   
The night following her operation, she is found trying to climb out of bed on the 
orthopaedic ward by one of the nurses.  She is trying to get out of bed as she 
believes that she is late for her train.  She starts to shout when the nurse tells her 
repeatedly to get back into bed.  Why do they not understand that she needs to get to 
the station to catch her train?  She becomes increasingly agitated and tries to push 
the nurse away when she attempts to manoeuvre her back into bed.  She has an 
aching in her hip, she feels thirsty and she just doesn’t understand what is going on.   
The sun eventually rises just as Mrs Smith has finally fallen asleep after a very 
disturbed night with lots of shouting and some ‘physical aggression’ reported by the 
nursing staff.   
The physiotherapist helps Mrs Smith to walk a short distance using a frame.  She 
notes that Mrs Smith is difficult to wake when she first arrives.  She also notes that 
she appears not to follow instructions well and appears distracted.  When Mrs 
Smith’s family visit in the afternoon, they are worried, as Mrs Smith seems to be 
repetitive and somewhat disorientated.  She believes that she has been in hospital 
for many days and tells her family that there was a fight on the ward overnight 
between a patient and an intruder.   
Mrs Smith is diagnosed with delirium by one of the junior doctors on the ward who 
notes that her cognitive test scores, routinely performed on first admission, have 
deteriorated significantly.  The doctor also acknowledges the family’s concerns that 
this behaviour is completely out of character.  They are very concerned about the 
sudden change they have seen in their relative.  They ask the doctor on the ward:  
“Will she get dementia?”   
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1.3 Definition  
Delirium is a sudden onset cognitive impairment, associated with acute illness, which 
tends to fluctuate, often being worse at night.  Delirium specifically impairs attention, 
with difficultly focusing, sustaining and shifting attention on a particular task, and 
causes derangements in level of arousal.  This results in a spectrum of presentations 
with some people being unusually sleepy and withdrawn, known as hypoactive 
delirium, and others appearing agitated and restless, known as hyperactive delirium.   
Delirium has been described for thousands of years.  Hippocrates is thought to have 
recorded some of the earliest descriptions of the syndrome, using multiple terms to 
describe the mental abnormalities caused by fever, poisoning or head trauma 
including ‘phrenitis’ (a state of frenzy) and ‘lethargus’ (inertia and dulling of senses) 
(Adamis et al., 2007).  The word delirium itself is derived from the Latin “de-lira”, 
meaning to go out of the furrow, and was recorded by Celsus as early as the first 
century AD (Adamis et al., 2007).   
The first formal classification did not emerge until the third edition of the American 
Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders 
(DSM-III) in 1980. This definition has subsequently evolved and the most recent 
edition, DSM 5 (American Psychiatric Association, 2013), is shown in Table 1.  In 
order to fulfil the criteria for delirium, patients must demonstrate each of the criteria A 
to E.  Without a biological marker for delirium, these criteria are the agreed gold 
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A. Disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift 
attention) and awareness (reduced orientation to the environment). 
B. The disturbance develops over a short period of time (usually hours to a few 
days), represents a change from baseline attention and awareness, and tends to 
fluctuate in severity during the course of a day. 
C. An additional disturbance in cognition (e.g., memory deficit, disorientation, 
language, visuospatial ability, or perception). 
D. The disturbances in criteria A and C are not explained by another pre-existing, 
established, or evolving neurocognitive disorder and do not occur in the context 
of a severely reduced level of arousal, such as coma. 
E. There is evidence from the history, physical examination, or laboratory findings 
that the disturbance is a direct physiologic consequence of another medical 
condition, substance intoxication or withdrawal (i.e., because of a drug of abuse or 
to a medication), or exposure to a toxin or is because of multiple aetiologies. 
Table 1: American Psychiatric Association Diagnostic and Statistical Manual of 
Mental Disorders Version 5 definition of delirium (American Psychiatric Association, 
2013) 
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1.4 Prevalence, Incidence and Occurrence Rates 
Delirium is a common complication associated with hospitalisation and has become 
synonymous with admission for many older people and their families.   
1.4.1 Hospital 
The point prevalence of delirium in all adult inpatients was found to be 19.6% in a 
study from a 400-bed district general hospital in Ireland (Ryan et al., 2013).  
Importantly, the prevalence increased with age (4.7% if <50 years and 34.8% if >80 
years) and varied according to setting, with the highest rates seen in geriatric 
medicine wards (53.3%) (Ryan et al., 2013).   
These findings were replicated in a multi-centre point prevalence study from Italy with 
overall prevalence of delirium of 22.9% (Bellelli et al., 2016).  This study included 
only those over 65 years of age.      
When examining older patients on admission to a general medical unit in Australia, 
the proportion with prevalent delirium, those with delirium on admission, was found to 
be 18% (Iseli et al., 2007).  The prevalence of delirium was slightly higher (24.6% of 
all admissions) in a study of routinely collected data from patients over the age of 65 
admitted acutely to a hospital in Scotland (Reynish et al., 2017).  Other studies of 
consecutive admissions to general medical or elderly care units report delirium 
prevalence from 10 to 31% (Siddiqi et al., 2006).   
In a study from South Wales, 37% of the 278 medical patients aged 75 years and 
older admitted acutely to a district general hospital were found to have delirium 
during their admission (Eeles et al., 2010).  These figures are echoed by systematic 
reviews which found occurrence rates per admission between 11 and 42% (Siddiqi et 
al., 2006) and 29 to 64% (Inouye et al., 2014) in general medical and old age 
medicine wards.  When focusing only on new episodes of delirium during admission, 
or incident delirium, rates per admission ranged from 3 to 29% (Siddiqi et al., 2006).   
Other areas of the hospital that see high rates of delirium are intensive care units, 
with between 45% and 87% of patients found to have delirium (Ely et al., 2001, 
Jackson and Khan, 2015) and palliative care wards, with incidence rates of 47% 
(Inouye et al., 2014).   
The prevalence of delirium in general surgical wards was found to be comparatively 
low at 7.2% when examining people of all ages (Ryan et al., 2013), but incidence 
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rates of 26.5% were found when focusing on surgical patients over 75 years (M.M. 
de Castro et al., 2014) and as high as 28.6% (Ryan et al., 2013) to 41% (Albrecht et 
al., 2015) in orthopaedic older patients. 
Although the exact figures vary considerably depending on the precise age and 
location of the populations studied and the time over which patients are examined, 
delirium remains the most common hospital acquired complication (Richardson et al., 
2016b). 
1.4.2 Community  
The number of older people living in the community with delirium is estimated to be 
low, with an overall prevalence around 1-2% (Inouye et al., 2014) and an estimated 
point-prevalence of 7.2 per 1,000 persons in those aged 55 years and older (Davis et 
al., 2013).   
The highest rates are seen in those with dementia (79.5 per 1,000 persons) (Davis et 
al., 2013) and the oldest old, with 100 per 1000 persons aged over 85 years 
experiencing delirium over a three year period in the Vantaa 85+ study (Davis et al, 
2012).  A similar prevalence in those aged over 85 years (10.1%) was obtained from 
the Cognitive Function and Ageing Study (CFAS) although the delirium was 
ascertained retrospectively using an algorithmic definition derived from the Geriatric 
Mental State examination (Davis et al., 2014). 
Higher rates of delirium are seen in care homes with a median point prevalence 
estimate from a systematic review of 14.2% in the United Kingdom (Siddiqi et al., 
2009) and a one month prevalence of 7.1% in one particular area of the UK (Siddiqi 
et al., 2016).  Prevalence rates were generally similar in residential (8.2%) and 
nursing homes (8.9%) in The Netherlands (Boorsma et al., 2012).  Prevalence rates 
are higher (33%) in those with advanced dementia defined as a MMSE score of less 
than 10 (McCusker et al., 2011).    




The cause of delirium is rarely due to a single factor and is most commonly due to 
the combination of underlying predisposing factors along with a number of 
contributing precipitating factors (Table 2) leading to a breach of the threshold for 
delirium (Figure 1).   
Predisposing factors for delirium Precipitating factors for delirium 
Older age (over 75 years) Medications (e.g. sedatives, opiates) 
Cognitive impairment and Dementia Bladder catheter 
History of delirium Physical restraint 
Functional impairment Physiological (e.g. electrolyte derangement) 
Visual impairment Infection 
Hearing impairment Surgery 
Comorbidity Trauma 
Depression Emergency admission 
Stroke 
Alcohol misuse 
Table 2: Predisposing and precipitating factors for delirium (Inouye et al., 2014) 
 
 
Figure 1: Graphical representation of the threshold for delirium. The size of the insult 
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Figure 1 demonstrates the inverse relationship between predisposing and 
precipitating factors when examining the threshold for delirium.  Consequently, a 
patient who has no predisposing factors which make them vulnerable would require a 
very large precipitant to push them over the threshold for developing delirium.  An 
example is a young, fit person who has a trauma, such as a road traffic collision, 
which results in multiple injuries, surgery and a prolonged stay in intensive care.  This 
hypothesis is supported by the high rates of delirium seen on wards with the most 
unwell patients (highest precipitant).  For example, over half of military personnel in 
intensive care following trauma (mean age 26 years) had at least one day of delirium 
(Bullock et al., 2015).  
Conversely, in someone who has multiple predisposing factors, for example an older 
person with cognitive and functional impairment, their high vulnerability to delirium 
means that even seemingly innocuous precipitants can push them over the threshold 
of delirium.  For example, changes in medication or the insertion of a urinary catheter 
can trigger delirium in vulnerable people.  This hypothesis explains why high rates of 
delirium are also seen on wards where people often have multiple predisposing 











Delirium was previously thought to be a relatively benign and transient condition.  We 
now know that this is not the case and evidence suggests that delirium is associated 
with a range of adverse outcomes. 
1.6.1 Distress 
Delirium is highly unpleasant and frightening for patients, their families and the staff 
caring for them.  As well as causing considerable distress at the time, delirium has 
been shown to be associated with long term psychological sequelae.   
Figures vary hugely in terms of the proportion of patients who recall their delirium, 
ranging from very few to almost all (Partridge et al., 2013).  A study of 101 inpatients 
with cancer, carried out following full resolution of their delirium, found that 53.5% of 
participants recalled their delirium (Breitbart et al., 2002).  They found that patients 
with more severe short term memory impairment at the time of their delirium, more 
severe delirium and patients with more severe perceptual disturbances were all 
significantly less likely to recall their delirium.  Other studies have shown that lower 
pre-delirium cognitive test scores are also associated with lower rates of delirium 
recall (Partridge et al., 2013).  However, a study specifically examining the 
experience of delirium in those with dementia found that of the 20 participants who 
were followed up 1 month after their episode of delirium, 13 recalled their delirium 
(65%) and the most frequently remembered symptoms were deficits in attention, 
apathy, psycho-motor retardation and anxiety/fear (Morandi et al., 2015). 
Breitbart et al retrospectively recorded distress associated with delirium using a 
validated tool and found that 80% of those who recalled their delirium reported 
severe distress, with the presence of delusions found to be the most significant 
predictor of patient distress (Breitbart et al., 2002).  Levels of distress were not 
affected by delirium motor subtype.  They also found that delirium was a highly 
distressing experience for relatives and staff looking after patients, with the distress 
of observing delirium in a relative sometimes being greater than the distress 
experienced by the patient themselves (Breitbart et al., 2002).  High levels of distress 
amongst relatives and carers has also been found in studies focusing on palliative 
care patients (Finucane et al., 2017). 
The majority of studies on the longer-term psychological impact of delirium are in 
intensive care unit survivors.  These studies suggest a link between delirium and 
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post-traumatic stress disorder, with a median point prevalence of between 19% and 
22%, along with anxiety and depression (Partridge et al., 2013).  However, existing 
data is limited by small sample sizes and inconsistent and varying methods for 
diagnosing delirium. 
1.6.2 Mortality 
It has been widely shown that delirium is associated with an increased risk of death 
(HR 1.95 [CI: 1.51 – 2.52] after a mean follow up of 22.7 months) (Witlox et al., 
2010).  In this analysis, the authors controlled for the potentially confounding effects 
of age, comorbidities or illness severity and baseline cognition.  In practice, this 
means that a patient with delirium in hospital is twice as likely to die as an identical 
patient, in terms of age, comorbidities or illness severity and baseline cognition, 
without delirium (Witlox et al., 2010).   
The relationship between delirium and increased inpatient mortality has been shown 
in a number of settings including general intensive care (Salluh et al., 2015) and 
cardiac intensive care (Pauley et al., 2015).  This relationship has also been shown 
to persist for 3 months, 6 months or a year following discharge from a number of 
settings including acute hospital (McCusker et al., 2002, Buurman et al., 2011), 
general medical and trauma wards (González et al., 2005), post-acute care facilities 
(Marcantonio et al., 2005), the emergency department (Israni et al., 2018, Han et al., 
2010a), palliative care wards (Lawlor et al., 2000), general medical wards (Rockwood 
et al., 1999) and following hip surgery (Kat et al., 2008).  In a study from London, 
81% of the participants with delirium had died within 3 years as opposed to 49% of 
those without delirium (Dani et al., 2018).  The impact of delirium on mortality has 
been shown to persist for up to 5 years after discharge (Eeles et al., 2010).    
This relationship has also been shown in community populations (Davis et al., 2014, 
Davis et al., 2012) including a study of community dwelling older people in Canada, 
which showed that delirium was associated with a very poor 5 year survival, similar to 
that of people with severe dementia (Andrew et al., 2006).   
Only one study has shown no link between delirium and mortality, although the 
results were limited by the small sample size in this study (Adamis et al., 2007).   
1.6.3 Inpatient complications 
People who have delirium during their hospitalisation have increased lengths of stay 
(Holmes and House, 2000, Siddiqi et al., 2006, Salluh et al., 2015) and have more 
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hospital-acquired complications, such as falls (Sillner et al., 2019) and pressure 
sores (Fong et al., 2015).     
1.6.4 Readmission 
Patients with delirium have been shown to be at increased risk of readmission, within 
30 days (LaHue et al., 2019, Marcantonio et al., 2005) and within the first year 
following discharge (Reynish et al., 2017). 
1.6.5 Financial 
An inpatient stay complicated by delirium leads to additional healthcare costs 
estimated at an extra £13,200 per admission (Akunne et al., 2012).  This figure 
comes from detailed cost-benefit analysis, which showed that multi-component 
interventions for delirium prevention in emergency admissions to general medicine 
were cost effective. 
1.6.6 Institutionalisation 
Delirium is associated with an increased risk of institutionalisation, or discharge to a 
care home, even when controlling for relevant confounders (OR 2.41 [CI: 1.77 – 
3.29]) (Witlox et al., 2010).  This was true on discharge from acute hospitals (Siddiqi 
et al., 2006) and post-acute care facilities (Marcantonio et al., 2005).  In fact, even 
when initially discharged home following an inpatient stay complicated by delirium, 
institutionalisation was higher in the first year following delirium (Eeles et al., 2010). 
1.6.7 Frailty 
Frailty is a state of increased vulnerability to minor stressors and reduced 
physiological reserve (Clegg et al., 2013).   There is a lack of a standardised working 
criteria for frailty and a lack of consensus regarding how best to measure it.  Although 
age has long since been identified as a significant risk factor for poor outcome, 
chronological age is highly heterogeneous.  It has been argued that frailty provides a 
more nuanced measure of function and may help to further risk stratify older persons 
(Bellelli et al., 2017).  
The relationship between frailty and delirium is complex and overlapping with 
delirium and frailty sharing many common features.  For example, both conditions are 
multifactorial, associated with increased mortality and generally negative outcomes 
and similar underlying pathophysiology has been proposed (Rockwood, 2004).  
Frailty is an independent risk factor for delirium (Persico et al., 2018) and delirium in 
itself has been shown to be associated with functional decline and general poor 
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outcome (Buurman et al., 2011).  Previous studies have shown that mortality rates 
following delirium are higher in those who are frail (Eeles et al., 2012).  Traditionally, 
it was thought that delirium was more dangerous in those who were more frail at 
baseline.  However, a recent study has shown that mortality rates following delirium 
were in fact highest in the least frail group (Dani et al., 2018).  Delirium and frailty, 
according to a 31-item frailty index, were both examined as exposures in this cohort 
of acutely admitted patients over 70 years in London: both were shown to 
independently predict the primary outcome of mortality up to 3 years after the index 
admission.  Given the predisposing and precipitating factors hypothesis and the 
threshold for delirium (Figure 1), the authors attempt to explain this perhaps 
unexpected finding by suggesting that in less frail individuals, the precipitant for 
delirium must be greater and therefore more likely to result in mortality (Dani et al., 
2018). 
Studies regarding the relationship between delirium and frailty are lacking and 
contradictory results are common (Bellelli et al., 2017).  Previous work is significantly 
limited by heterogeneity in the definition and measurement of delirium and frailty.  
Only eight studies qualified for a recent meta-analysis and many of these studies 
were assessed to be methodologically suboptimal (Persico et al., 2018).  A further 
limitation of previous work is that frailty has often been viewed as a dichotomous 
variable, either present or absent, using an arbitrary cut off.   
1.6.8 Predicting poor outcomes 
In a systematic literature review examining predictors of poor outcomes in older 
hospital patients, delirium related factors including hypoactive motor subtype, more 
severe delirium and longer delirium duration were all found to predict both mortality 
and new institutionalisation, along with co-morbid dementia and depression (Jackson 
et al., 2016b).  A number of patient related factors and biomarkers were also found to 
be associated with both mortality and institutionalisation and these are summarised 
in Table 3. 
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Outcome Predictors identified, in order of frequency 
Mortality 1 month Hypoactive subtype, length of delirium, delirium and 
depression 
1-6 months Hypoactive subtype, severity of delirium, dementia, length of 
delirium, hyperactive subtype, age, lower serum albumin, 
missed diagnosis 
≥1 year Length of delirium, hypoactive subtype, dementia, no dementia, 
illness severity, age, hospital length of stay 
Reduced 
survival time 
Length of delirium, frailty, age, raised cerebrospinal fluid 
5-hydroxyindoleacetic acid, raised CSF acetylcholinesterase 
activity 
New institutionalisation Persistent delirium, delirium and depression, delirium severity, 
hyperactive subtype 
Table 3: Predictors of mortality and new institutionalisation identified by a literature 
review on predictors of outcome after delirium (Jackson et al., 2016b) (table taken 
directly from paper) 
A missed diagnosis of delirium in the emergency department was also associated 
with significantly increased mortality at 6 months (Kakuma et al., 2003), although this 
was a relatively small study. 
When the systematic review by Jackson et al was published (Jackson et al., 2016b), 
there were no studies found which specifically examined predictors of cognitive 
outcome.  Subsequently, a study has shown that patients with the highest delirium 
severity, rated according to the Confusion Assessment Method-Severity (CAM-S), 
experienced the greatest rate of cognitive decline up to 36 months after surgery and 
higher mortality (Vasunilashorn et al., 2018).  The cohort studied was 70 years and 
over and all undergoing major elective non-cardiac surgery.  A significant limitation of 
the study, along with the lack of generalizability of the cohort, was the fact that 
baseline cognition was not accounted for in the analysis.  The following section will 
discuss why this is problematic.  
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1.7 Delirium and dementia 
1.7.1 Delirium superimposed on dementia 
Dementia is a major risk factor for delirium (Inouye et al., 2014, Fong et al., 2015) 
and the two frequently co-exist, with prevalence rates between 22% and 89% (Fick et 
al., 2002).  Delirium superimposed on dementia (DSD) is associated with 
considerable distress (Morandi et al., 2015) and worse outcomes, in terms of 
mortality, functional dependence, institutionalisation and length of stay, when 
compared to either delirium or dementia alone (Bellelli et al., 2007, Morandi et al., 
2014, Reynish et al., 2017).  Prevalence of delirium appears to vary according to 
dementia subtype, with the highest prevalence of delirium amongst those with 
Dementia with Lewy Bodies (DLB) (Vardy et al., 2014) and vascular dementia 
(Hasegawa et al., 2013). 
1.7.2 Delirium as a risk factor for dementia 
“Is delirium simply a marker of vulnerability to dementia, or does delirium itself lead to 
dementia?” (Inouye et al., 2014) 
The relationship between delirium and dementia is complex.  Dementia is a major 
risk factor for delirium but emerging literature indicates that delirium is a strong 
predictor of new-onset dementia as well as acceleration of existing cognitive decline 
(Jackson et al., 2004, MacLullich et al., 2009, Fong et al., 2015).  This is consistent 
across several different settings: after hospitalisation (Witlox et al., 2010); in those 
with dementia (Fong et al., 2009, Gross et al., 2012); in post-operative patients 
(Bickel et al., 2008, Lingehall et al., 2017, Saczynski et al., 2012); after critical care 
(Pandharipande et al., 2013); and in community populations (Davis et al., 2012, Tsui 
et al., 2018, Davis et al., 2014).  Cognitive decline has also been shown to be 
significantly greater following an episode of sub-syndromal delirium (Cole et al., 
2003a), defined as having one or more features of delirium, without having the full 
syndrome. 
In terms of quantifying the size of the impact of delirium on cognitive decline and risk 
of dementia, a population-based study of over 85 year olds showed an 8 fold 
increased risk of cognitive decline following an episode of delirium (OR 8.7 [CI: 2.1-
35.0]) (Davis et al., 2012).  A similar risk of cognitive decline was seen in a younger, 
population-based cohort from the UK (OR 8.8 [CI: 2.8-28.0]) (Davis et al., 2014) and 
an elective cardiac surgery cohort (OR 7.57 [CI: 2.15-26.65]) (Lingehall et al., 2017).  
An almost 2 point reduction on the Addenbrooke's Cognitive Examination was 
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associated with self-reported symptoms of delirium over the seventh decade (-1.7 
points [CI: -3.2 - -0.1]) (Tsui et al., 2018).  In people with dementia, delirium was 
associated with twice the rate of cognitive decline than in those without delirium over 
5 or more years (Gross et al., 2012).  A biphasic decline in cognition was seen after 
surgery with an acute decline and then recovery by 2 months, followed by gradual 
decline over 36 months (Inouye et al., 2016).  This may explain why no association 
was found between delirium and cognitive decline measured at just 6 months post 
aortic valve surgery (Eide et al., 2016).   
There are very few studies which have examined cognitive outcomes after delirium 
whilst controlling adequately for baseline cognition.  It is vital to adequately and 
robustly ascertain baseline cognition in order to determine whether any cognitive 
decline observed following delirium is new or pre-existing but undiagnosed.  This is 
crucial when testing the hypothesis that delirium is not simply a marker of 
vulnerability but is, in fact, leading to cognitive decline. 
The few studies that do attempt to control for baseline cognition are summarised in 
Table 4 along with the limitations of each study, which will be discussed in more 
detail below.   
Very few of these studies have accounted for the confounding effect of illness 
severity.  Acute hospitalisation itself has been shown to adversely affect trajectories 
of cognitive decline, even when delirium has not been specifically ascertained 
(Ehlenbach et al., 2010, Wilson et al., 2012, Mathews et al., 2014). This implies that 
delirium and/or its acute causes can contribute to the overall burden of dementia.  
Pulling apart the attributable components of cognitive decline is crucial to our 
understanding of the consequences of delirium. 
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Study Sample Sample 
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Study Sample Sample 
size 










size (95% CI) 
Limitations 
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Interviewer’s 

















et al., 2013) 
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SOFA daily 61 74% −5·6 points per day 
of delirium 










Gross et al, 















Blessed IMC test 
score over 5 or more 
years 
None 78 56% Additional 1·2 
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Study Sample Sample 
size 










size (95% CI) 
Limitations 




Patients aged ≥60 
years undergoing 
elective CABG or 
valve surgery 
225 CAM daily Trajectory of MMSE 
change over 1 year 
None 73 46% Prolonged 
impairment in 
recovery. Mean 
MMSE scores at 6 
and 12 months 









Davis et al, 
2012 (Davis et 
al., 2012) 
Population-based 
sample of all 
residents aged ≥85 
years 
553 Participant and 
informant 
interview, along 




clinician) at 2·5 
years 





Fong et al, 















Blessed IMC test 
score over 0·7 years 






Bickel et al, 
2008 (Bickel et 
al., 2008) 




200 CAM Cognitive 
impairment or 
dementia, or both 










patients aged ≥65 
years with acute 
hip fracture 
78 DSM-IV Consensus diagnosis 
of dementia at 5 
years 







Table 4: Summary of studies which examine cognitive outcomes after delirium whilst controlling for baseline cognition.  Headline 
results and limitations included.  Table adapted from Inouye et al, 2015.  
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1.7.3 Persistent delirium 
Most delirium tends to resolve over several days to a few weeks.  However, delirium 
can persist for several months, which is known as persistent delirium.  Persistent 
delirium is poorly researched with no widely accepted definition.  In a review of the 
topic (Cole et al., 2008), persistent delirium was defined as delirium which persisted 
throughout hospital admission and was present at follow up.  The prevalence of 
persistent delirium at 1, 3 and 6 months after discharge was found to be 32.8%, 
25.6% and 21% respectively (Cole et al., 2008).  In a study from Birmingham which 
reviewed people with delirium at 3 months, 6% had persistent delirium (Jackson et 
al., 2016a).  A major limitation in these studies is that it was not possible to determine 
whether the patient had the same episode of delirium, which had persisted 
throughout the follow up period, or whether a new delirium had developed following 
the resolution of the previous episode.   
It is usually not possible to make a diagnosis of dementia in the presence of delirium 
as it is unclear whether the cognitive deficits demonstrated will resolve.  The 
diagnosis of dementia is based upon the demonstration of progressive cognitive 
impairment over a period of at least 6 months which significantly impacts upon 
activities of daily living (American Psychiatric Association, 2013).  However, if 
delirium truly persists beyond 6 months, the margins between the definitions of 
delirium and dementia become blurred and it can be very difficult to know whether 
the patient will ever recover or whether their current state is their new baseline.  
  
Chapter 1: Introduction 
20 
 
1.8 Limitations of current literature 
Delirium was previously thought to be a benign and transient condition and, 
consequently, is under-researched, well out of proportion to its prevalence and 
impact. The studies that do exist have a number of crucial limitations. 
1.8.1 Variations in diagnostic criteria  
Current delirium research is limited by huge variations in the methods used to 
ascertain delirium.  This is apparent when comparing the varied figures quoted for 
prevalence, incidence and occurrence rates across different studies.   
In the absence of a biomarker, clinical criteria provide the gold standard for delirium 
diagnosis.  The most widely used of these is the Diagnostic and Statistical Manual 
criteria, now in its 5th edition (Table 1) (American Psychiatric Association, 2013).  
Over time, there have been several revisions of the DSM criteria, with subtle 
differences in the criteria.  An alternative classification is produced by the World 
Health Organisation and first appeared in the 10th edition of the International 
Classification of Diseases (ICD) (World Health Organization, 1992).   
Although there is considerable overlap between the various iterations of the DSM 
criteria and the ICD criteria, studies have shown that these subtle differences impact 
on the rates of delirium reported in both hospital and care home settings, with only a 
small proportion of patients meeting all criteria (Laurila et al., 2003, Adamis et al., 
2015, Cole et al., 2003b, Voyer et al., 2009, Meagher et al., 2014b).  The 
classification system used for delirium has also been shown to identify populations 
with differing outcomes in terms of mortality, length of stay and institutionalisation 
(Adamis et al., 2018).   
The water is further muddied by studies which diagnose delirium using tools such as 
the Confusion Assessment Method (CAM) (Inouye et al., 1990).  Designed primarily 
as a screening tool rather than a diagnostic tool, the CAM does operationalise 
aspects of the diagnostic criteria it was based upon (DSM-III-R) but remains 
subjective, time consuming and requires considerable training to obtain the sensitivity 
and specificity quoted in the original studies (Green et al., 2019).   
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1.8.2 Operationalising the criteria 
The diagnostic criteria state the features that must be demonstrated in order for a 
diagnosis of delirium to be made but offer only limited guidance on how best to do 
this.  This leaves the diagnostic criteria open to individual interpretation and the 
diagnosis subjective.  There is significant variability in the reference standard 
methods used for delirium diagnosis in published delirium research studies (Neufeld 
et al., 2014).  This makes the comparison of studies challenging and the 
heterogeneity of case ascertainment is sited as a significant limitation in the majority 
of delirium literature reviews and meta-analyses.  Clinically, this may have 
contributed to the considerable uncertainty amongst clinicians regarding how to 
diagnose delirium (Jenkin et al., 2016) and the extensive heterogeneity in clinical 
practice, particularly with respect to delirium superimposed on dementia (Richardson 
et al., 2016a).   
There is no guidance regarding how to test for key features of the DSM 5 criteria 
including inattention and cognitive impairment, and very little research specifically 
evaluates tests for these in the context of delirium.  There are also features of the 
delirium itself that make the diagnosis particularly challenging to make.  One such 
situation is the assessment of delirium in the context of severely deranged level of 
consciousness or alertness.  Patients can either be too drowsy or too hyperactive to 
engage with formal testing, rendering them ‘untestable’.  As such, arousal and 
attention are hierarchically related whereby level of consciousness must be sufficient 
in order to demonstrate disorders of attention (Figure 2).  15% of delirium research 
studies excluded these patients (Neufeld et al., 2014) but this clearly introduces 
significant bias, particularly as hypoactive delirium has been associated with worse 
outcomes (Jackson et al., 2016b).  




Figure 2: Diagrammatic representation of the hierarchical relationship between level 
of arousal and attention in delirium.  Patients with very deranged level of arousal are 
unable to complete most of the tests used to assess for delirium 
 
DSM-5 only offers brief guidance on this but an approach has been proposed which 
recommends that the inability to engage in cognitive testing or interview is 
considered severe inattention for the purposes of delirium diagnosis (European 
Delirium Association and American Delirium Society, 2014).  This “relaxed” 
interpretation of the DSM 5 criteria has been shown to be more inclusive (Meagher et 
al., 2014b).   
Standardising a clear definition of delirium is essential to ensure consistent case 
ascertainment in future delirium research and ensure results of studies are 
comparable.  The optimal operationalisation of DSM 5 criteria is currently elusive but 
will require reliable and valid tests of inattention, cognition and neuropsychiatric 
symptoms with clear guidance regarding what to do when people are unable to 
complete the tests due to advanced dementia or very deranged level of arousal.  
Until this time, greater transparency amongst delirium researchers regarding the 
methodology used for delirium diagnosis, in the form of a table showing how each 
component of DSM 5 was operationalised, would facilitate better comparisons 
between studies and more consistency in delirium research.  Authors should also be 
encouraged to publish the processes they used to capture information from patients 
unable to participate in formal testing.  One approach to determine whether delirium 
is present or absent in research studies is to use a consensus panel to review 
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vignettes for each participant containing data collected prospectively regarding each 
of the components of DSM 5 criteria. 
1.8.3 Delirium Superimposed on Dementia 
The clinical phenotypes of delirium and dementia show considerable overlap, which 
makes diagnosing delirium in the context of dementia challenging.  In the absence of 
specific tools or guidance for the application of diagnostic criteria in the context of 
pre-existing dementia, delirium superimposed on dementia (DSD) is currently 
evaluated with instruments used for diagnosing delirium alone (Morandi et al., 2012).  
This is problematic given that many of these tools rely on cognitive tests, which may 
be abnormal in both dementia and delirium (Meagher et al., 2010, Tieges et al., 
2014).  Therefore, in order to differentiate the two conditions, the diagnosis of 
delirium relies upon the demonstration that there has been an acute change from the 
patient’s baseline (Criterion D from Table 1).  This depends upon the availability of a 
reliable informant who can provide an accurate collateral history of an acute change, 
which is often problematic in the acute setting.  This may delay diagnosis or result in 
delirium being missed, along with its potentially treatable cause, as people commonly 
assume that the abnormalities detected on cognitive testing are due to underlying 
dementia rather than delirium.  This emphasises the need for robust knowledge of 
baseline cognitive status in delirium research studies. 
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1.8.4 Poor recognition and documentation of delirium 
Despite its high prevalence and poor outcomes, the diagnosis of delirium is 
frequently missed.  A study of 710 acute elderly medical admissions found that 72% 
of the 110 cases of delirium were not detected by the clinical teams (Collins et al., 
2010).  These findings have been replicated throughout the hospital (Ryan et al., 
2013) including the emergency department where it is estimated that 57% to 83% of 
cases are missed (Han et al., 2010b).  Delirium is also poorly documented and 
under-recorded (Milisen et al., 2002).  Unfortunately, missing the diagnosis of 
delirium is associated with worse outcomes, including mortality (Kakuma et al., 
2003).   
The reasons for the poor recognition of delirium are complex.  A lack of knowledge 
about delirium (Davis and MacLullich, 2009), particularly the diagnostic criteria 
(Jenkin et al., 2016), and uncertainty regarding differentiating delirium from dementia 
have been demonstrated (Steis and Fick, 2011).  However, beyond gaps in 
knowledge, there remain significant attitudinal barriers to improving delirium care, 
with a lack of ownership and a general lack of awareness of its importance 
(Teodorczuk et al., 2013).   Hospitals are not currently designed for frail older people 
(Richardson et al., 2016b) and time constraints have been listed as a reason for not 
routinely screening people for cognitive impairment (Kennelly et al., 2013).  There is 
also significant uncertainty regarding patients with delirium who are ‘untestable’, as 
discussed previously, with screening tools often left incomplete for these patients, 
which may in itself be a sign of adverse outcomes (Eeles et al., 2009). 
The poor recognition and documentation of delirium has important implications for 
research studies that rely on the retrospective ascertainment of delirium from case 
notes.   
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1.8.5 Methodological issues in cohort studies 
1.8.5.1 Selection bias 
In existing delirium research, there is a lack of good quality, large epidemiological 
studies in unselected populations.  A number of studies simply exclude participants 
with dementia, despite the fact it is a major risk factor for delirium, probably resulting 
in an underestimation of the true incidence of delirium.  Due to the association 
between illness and delirium, many of the studies sample inpatient populations.  
Even within this setting, highly selected participants are often studied such as 
surgical patients, a particularly appealing cohort to study due to the ease of case 
finding, baseline assessment and the clear timing of a precipitant i.e. surgery.  
However, this selection bias towards a population fit enough for major surgery, 
renders these studies non-generalisable to the majority of patients seen in hospital 
who are considerably frailer.     
1.8.5.2 Incomplete ascertainment of baseline cognition 
It is likely that previous studies may have been confounded by incomplete 
ascertainment of cognitive status at baseline (Davis et al., 2012), particularly given 
that around half of dementia is undiagnosed (Sampson et al., 2009).  Other studies 
have attempted to address the lack of baseline cognitive assessments by using tools 
such as the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) to 
assess baseline cognition.  A recent study aiming to address the lack of evidence for 
its use in hospital patients with delirium found that it performed well at a cut-off >3.82 
for detecting dementia (sensitivity 0.91 [CI: 0.79–0.97]; specificity 0.93 [CI: 0.76–
0.99]) (Jackson et al., 2016a).  However, these retrospective measures do not give 
any quantitative information on pre-delirium cognition, particularly not for specific 
domains, and it is not possible to subtype any dementia present.   
1.8.5.3 Lack of prospective delirium assessments 
A major limitation of the few population studies of cognitive trajectories in delirium 
that have included extensive baseline cognitive assessments is the fact that delirium 
could not be prospectively defined (Davis et al., 2012, Tsui et al., 2018, Davis et al., 
2014).  As well as being susceptible to recall bias, particularly in the context of 
residual cognitive impairment, and poor documentation, retrospective ascertainment 
only allows delirium to be viewed as a dichotomous variable, which may be 
misleading.  It is probable that delirium characteristics such as motor subtype, 
duration and aetiology, may impact upon outcomes (Jackson et al., 2016b).   
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1.8.5.4 Controlling for illness severity 
Retrospective ascertainment of delirium is also limited by the fact that it is not 
possible to control for the potentially confounding effect of simultaneous illness 
severity.  Is it simply the case that those who had delirium were just sicker, and it was 
this underlying illness that resulted in their cognitive impairment or is delirium itself 
neurotoxic?  These are fundamental questions which can only be answered in a 
robustly designed population-based cohort study with prospective delirium 
assessments which adequately control for illness severity.   
Two studies have attempted to account for illness severity (Table 4) in the context of 
a cohort study.  Although both studies demonstrated that delirium was associated 
with cognitive decline even when controlling for illness severity, both had significant 
methodological limitations.  One study used the interviewer’s rating (none, mild, 
moderate, severe) of any current acute illness (Davis et al., 2014).  This is non-
validated and highly subjective.  The other study used the Sequential Organ Failure 
Assessment (SOFA) (Vincent et al., 1996), a validated tool for the assessment of 
illness severity, but this study was limited by a young, non-generalisable intensive 
care population and excluded participants with severe dementia (Pandharipande et 
al., 2013).   
The optimal method of ascertaining illness severity in a hospitalised older population 
is unknown as there are a lack of validated tools to measure illness severity in older 
people.  Two of the most frequently cited illness severity scores, Acute Physiology 
and Chronic Health Evaluation II (APACHE-II) (Knaus et al., 1985) and the Simplified 
Acute Physiology Score II (SAPS-II) (Le Gall et al., 1993), were designed for use on 
admission to the intensive care unit to predict mortality.  These severity rating scales 
have not been validated for use outside of intensive care and include variables that 
are not commonly recorded in general medical patients including pH and arterial 
oxygen concentrations.  The SOFA was also designed for use on admission to 
intensive care and includes these variables.  However, unlike APACHE-II and SAPS-
II, SOFA was also designed for use every 24 hours until discharge.  It records the 
worst parameters measured over the preceding 24 hours to produce a mortality 
prediction score based on the degree of dysfunction of six organ systems.   
As a compromise, other delirium studies have used a modified version of APACHE II, 
without the components which are not routinely recorded outside of the intensive 
care unit (Jackson et al., 2016a).    
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1.9 Moving forward: introduction to the DECIDE study 
In a population-based cohort study of men and women aged 65 years and older, the 
DECIDE study measured the effect on cognition of an episode of delirium, 
independent of baseline cognitive status and illness severity. The study also explored 
the predictive value of clinical parameters, including delirium severity, duration and 
subtype, on cognitive outcomes following an episode of delirium. 
The DECIDE study was nested within the MRC Cognitive Function and Ageing Study 
II (CFAS II).  This is a large, population-based cohort of community dwelling 
individuals aged 65 years and over from five geographical areas in the UK, which 
aimed to investigate dementia and cognitive decline.  The CFAS studies have 
provided unique data on prevalence, risk factors, service needs and financial 
implications of dementia within the UK (Matthews et al., 2013).   
The nesting of a prospective delirium study within CFAS II provided a unique 
opportunity to use an existing, well-characterised and representative, population-
based cohort to avoid the selection biases associated with much of the current 
literature based solely on hospitalised samples (Davis et al., 2013, Brayne and Davis, 
2012).   
The DECIDE study recruited hospital attending CFAS II – Newcastle participants and 
followed them throughout their hospital stays in order to identify delirium.  Those 
recruited were followed up one year after their discharge to repeat their CFAS 
interviews.  Before and after cognitive test scores were compared in those with and 
without delirium, whilst controlling for relevant confounding factors including illness 
severity. 
This was an exceptional opportunity to answer questions of major clinical significance 
and to guide clinicians, patients, families and researchers as well as making full use 
of, and adding value to an existing cohort study.  The prospective nature of the 
delirium assessments, and the data to be collected, will increase understanding of 
the natural history of delirium.  As such, this study could address many unanswered 
questions of clinical significance in delirium.  This will facilitate accurate and realistic 
conversations with families and will have important implications for healthcare 
planning and resource allocation.  
If delirium is robustly associated with trajectories of cognitive decline, it is reasonable 
to hypothesise that delirium is a potentially modifiable risk factor for dementia. Given 
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that delirium is preventable in around one third of cases (Inouye et al., 1999), this 
paves the way for future dementia prevention trials that focus on delirium 
intervention. Given the current lack of treatments for dementia, and the ageing 
population, prevention is becoming increasingly relevant and appealing.   




Despite being first described more than 2000 years ago, “delirium remains hard to 
define and difficult to study” (Adamis et al., 2007).  Much of the existing research is 
limited by inconsistencies with case ascertainment and highly selected populations.  
The nesting of a prospective delirium study that prospectively tracks cognitive 
change before, during and after delirium within a well-characterised, representative 
cohort with known baseline cognition will provide a unique opportunity to answer 
questions of major significance to patients, their family and the population as a 
whole. 
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2.1 Design  
The Delirium and Cognitive Impact in Dementia (DECIDE) study is a nested 
prospective longitudinal cohort study.  The protocol for the study has been published 
(Richardson et al., 2017) (Appendix A). 
2.2 Aims 
To explore the association between delirium and cognitive decline, independent of 
baseline cognition and illness severity. 
2.3 Objectives   
In a population-based cohort study of men and women aged 65 years and older:                                                                                                                                               
• To measure the effect on cognition of an episode of delirium, independent of 
baseline cognition and illness severity 
• To explore the predictive value of clinical parameters (including delirium 
severity, subtype and duration) on cognitive outcomes following an episode of 
delirium 
2.4 Population  
The DECIDE study was embedded within the Cognitive Function and Ageing Study 
II-Newcastle centre (CFAS II-Newcastle).  This is a large, population-based cohort of 
individuals from five geographical areas in the UK.  The protocol for this study is 
published online (http://www.cfas.ac.uk/cfas-ii/cfasii-study-design/) but the details are 
as follows. 
2.4.1 CFAS II-Newcastle baseline assessments 
At baseline (2008-2011), 2500 participants aged ≥65 years were recruited using 
primary care registration, which included care settings, to CFAS II-Newcastle.  The 
UK system of primary care registration provides the “most robust population base for 
sampling by age group for epidemiological studies in the UK” (Matthews et al., 2013).  
Sampling was stratified by age to ensure that there were 1,250 individuals aged 65-




74 and 1,250 individuals aged 75 years and over.  Interviews were undertaken over a 
two-year period.  Participants were re-seen two years later, again over a two-year 
period.   
The interviews were carried out and entered directly onto a laptop computer.  The 
interview collected information regarding demographics such as age at time of 
interview, gender, place of residence and years of education, lifestyle variables, 
health status, functional limitations, social support, measures of hearing and visual 
impairment, and receipt of health services.  Social class according to the main 
occupation of the participant and their partner, where applicable, was calculated from 
this data and divided according to the categories in Figure 3 based upon the 
Standard Occupational Classification (SOC) developed by the UK Office for National 
Statistics.  
I -  Professional occupations  
II -  Managerial and technical occupations  
IIIN -  Skilled non-manual occupations  
IIIM -  Skilled manual occupations  
IV -  Partly-skilled occupations  
V -  Unskilled occupations 
Figure 3: Social class categories based on occupation  
The Modified Townsend Disability Scale was also calculated based on the data 
collected at the interviews.  This scale rates functional incapacity and consists of 9 
activities which are rated as follows: 2 if help needed; 1 if some difficulty or used aids 
in order to complete the activity; and 0 if no difficulty and did not need any aids.  The 
activities are: cutting own toenails, washing all over or bathing, getting on a bus, 
going up and down stairs, heavy housework, shopping and carrying heavy bags, 
preparing and cooking a hot meal, reaching an overhead shelf and tying a good knot 
in string.  The scores from these activities are added up to form a score from 0 – 18 
where 0 is no functional incapacity and 18 is very severe functional incapacity.  The 
total scores were dichotomized where a score of 1 was given if the total score was 
11-18, and 0 if the total score was 0-10. 




2.4.2 CFAS II-Newcastle cognitive function assessments 
Global as well as domain specific cognitive function was assessed at baseline and 
two years follow-up using the Geriatric Mental State (GMS), the Cambridge Cognitive 
Examination (CAMCOG) and the Mini Mental State Examination (MMSE).  An 
algorithmic approach to the diagnosis of dementia, depression and anxiety was also 
possible within the interview using the AGECAT (Automated Geriatric Examination 
for Computer Assisted Taxonomy), drawing on respondent and observer ratings.  
This method has previously been validated and shown to be reliable (Copeland et al., 
1986).  In 20%, an informant interview was also conducted for the refinement of 
study diagnosis and to provide essential proxy information where respondents were 
unable to answer questions.  The full content of the interviews is available on the 
CFAS website (http://www.cfas.ac.uk/). 
If participants were unable to complete the full interview, often due to severe 
cognitive impairment, resulting in missing data and preventing an algorithm 
diagnosis, a review of all available information was completed by a diagnostician, 
applying DSM-IIIR criteria (Matthews et al., 2013).   
2.5 Recruitment   
2.5.1 Contacting General Practitioners of potential participants 
At the start of the DECIDE study, the General Practitioners (GPs) of all of the 
participants in CFAS II-Newcastle were contacted in order to confirm the 
appropriateness of re-contact with surviving members.  They were asked to notify the 
CFAS team if they felt there was any reason why participants should not be 
approached, including patients no longer being registered with the surgery or if there 
was a medical reason such as end stage terminal illness.  As one of the main 
focuses of the study was cognition and ageing, surgeries were requested not to 
exclude participants because they had dementia or were living in institutions. 
 
2.5.2 Contacting potential participants via CFAS 
In those surviving members of CFAS II-Newcastle whom the GPs felt it acceptable to 
re-contact, an introductory letter and participant information sheet was sent by the 
CFAS team detailing the proposed DECIDE study.  Participants were invited to 
contact the CFAS team if they did not want their NHS number to be shared with the 




DECIDE study team.  All surviving CFAS II-Newcastle participants were eligible to 
participate in DECIDE. 
 
2.5.3 Recruiting participants into the DECIDE study during an admission to 
hospital 
All participants sampled in CFAS II-Newcastle live within the catchment area of the 
Newcastle-upon-Tyne Hospitals NHS Foundation Trust.   
During a one-year period from 5th January 2016 to 5th January 2017, participants of 
CFAS II-Newcastle were approached on emergency or elective admission to 
hospital.  In order to identify participants admitted to hospital, a Recurring Admission 
Patient Alert (RAPA) was set up on the Newcastle upon Tyne hospitals electronic 
records system.  This flagged up participants on admission to the two acute hospitals 
in the Newcastle Hospitals NHS Foundation Trust (Royal Victoria Infirmary and 
Freeman Hospital).  They were then approached as soon as possible following 
admission and invited to take part in the DECIDE study.  Once recruited, they were 
seen on each subsequent hospital admission if agreeable verbally.  As such, they 
were not asked to provide written consent on each subsequent hospital admission 
during the study period. 
 
  




2.6 Inclusion criteria 
Any participant in CFAS II-Newcastle admitted to hospital during the recruitment 
period from 5th January 2016 to 5th January 2017 was invited to take part.  If the 
participant themselves lacked capacity, according to a capacity assessment 
performed by the lead researcher (SR), an appropriate personal consultee was 
sought and invited to provide written confirmation of willingness to participate.  
 
2.7 Exclusion criteria 
Patients were excluded from the study if they lacked capacity to consent and the 
study team were unable to identify or contact an appropriate personal consultee.  
Participants were also excluded if they were receiving end of life care.  If the patient 
was being isolated for infection control reasons, invitation to participate was delayed 
until they were no longer being isolated.  Participants who were expected to be in 
hospital for less than 24 hours were not invited to participate. 
 
  




2.8 Consent   
Potential participants were approached as soon as possible on admission to hospital.  
This did not interfere with clinical care.  They were approached by the chief 
investigator (SR) or the research nurse and provided with another copy of the 
participant information sheet.  Participants were given a maximum of 24 hours to 
decide whether they would like to take part in the study.  However, given the low risk 
and largely observational nature of the study, along with the fact that all participants 
had previously been notified of the study by post and provided with a participant 
information sheet, many participants and their personal consultees were willing to 
consent before this.   
 
2.8.1 Capacity 
The inclusion of some participants lacking capacity was inevitable as the study aimed 
to look at the effect of delirium on cognition and both delirium and dementia can 
impair a person's capacity.  A formal capacity assessment based on the Mental 
Capacity Act was performed by a trained member of the research team, mainly the 
chief investigator (SR). Participants were asked to give consent appropriate to their 
level of understanding, ranging from written informed consent to account being taken 
of verbal and non-verbal communication in determining willingness to participate. In 
those individuals found to be without capacity to give full written informed consent, a 
personal consultee was identified, and their advice sought regarding participation as 
per Section 32 of the Mental Capacity Act (Great Britain, 2005).  As per this 
guidance, the personal consultee was not a paid carer. 
 
The advantage of re-evaluating CFAS II participants, as opposed to other study 
populations, is that they have already expressed an interest in research by virtue of 
their willingness to participate in CFAS II. This made conversations with the personal 
consultee easier as they were familiar with research and aware of the wishes and 
feelings of the participant about taking part in research studies.  
 
2.8.2 Continued consent process 
Verbal reconfirmation of the study participant’s willingness to continue with the study 
was sought at each point of contact. Participants who were very distressed or 
refused to engage (whether due to delirium or having the capacity to refuse 
assessment on that occasion) were not assessed by the research team on that 




occasion but a record of the outcome of the interaction was documented.  Due to the 
fluctuating nature of delirium, further contact was attempted later.  Any patient 
appearing consistently distressed by participation or withdrawing consent whilst 
having capacity were excluded from the study without prejudice to clinical care.  As 
such, every effort was made to respect the wishes of the person, both previously 
made and at the time the research was undertaken. 
 
If they recovered capacity, participants admitted to the study via a personal consultee 
were given the opportunity to consider whether they would like to continue to be part 
of the study and if so, written consent was obtained. 
 
2.9 Data collection  
Following recruitment to the DECIDE study, data was collected as per the example 
flowcharts below (Figure 4 and Figure 5) and detailed in this section and Appendix B.  
Each participant had demographic information collected on just one occasion 
regardless of the number of admissions during the study period.  Admission 
information was collected once on each admission.  Daily review documentation was 
completed each time the participant was reviewed during their admission.  

































Figure 4: Flowchart to demonstrate the structure of data collection for a participant 
admitted on one occasion during the study period for 3 days  
Demographics 
Admission information 
for admission 1 
Daily review on Day 
1 of Admission 1 
Daily review of Day 2 
of Admission 1 
Daily review of Day 3 
of Admission 1 
Discharged 
























Figure 5: Flowchart to demonstrate the structure of data collection for a participant 




for admission 1 
Admission information 
for admission 2 
Admission information 
for admission 3 
Daily review on Day 
1 of Admission 1 
Daily review of Day 2 
of Admission 1 
Demographics 
Discharged 
Daily review on Day 
1 of Admission 2 
Daily review of Day 2 
of Admission 2 
Daily review of Day 3 
of Admission 2 
Daily review of Day 4 
of Admission 2 
Discharged 
Daily review on Day 
1 of Admission 3 
Discharged 





Demographic data was collected on just one occasion from the participant, their 
informant, if available, and from the medical records following consent being obtained 
and not repeated on subsequent admissions.  The data collected included age, 
gender, co-morbidity, whether there was a history of delirium prior to the study period 
documented in the clinical records and whether there was a history of delirium from 
the patient or their informant.  Previous episodes of delirium are a recognised 
predisposing factor for further episodes of delirium (Inouye et al., 2014) but it is 
notoriously poorly documented (Milisen et al., 2002). 
2.9.1.1 Recording co-morbidity 
The previous medical history of the participants was recorded in a structured way 
according to the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) (Miller et al., 
1992).  It was then possible to score patients in each of fourteen categories 
representing clinically relevant body systems according to severity, rated from 0 to 4, 
as per the 1991 manual (Figure 6).  The information for the completion of the CIRS-G 
was obtained mostly from medical records with come clarification from participants or 
their consultee.   
2.9.1.2 Choice of measure of co-morbidity 
The CIRS-G was chosen over other measures of co-morbidity, such as the Charlsson 
index (Charlson et al., 1987), because it was developed specifically for use in older 
people.  It is derived from the Cumulative Illness Rating Scale (Linn et al., 1968), 
which, in itself, has been shown to be a valid and reliable measure of co-morbidity for 
use in clinical research (de Groot et al., 2003).  The CIRS-G showed good interrater 
reliability for total scores and is accompanied by a useful and comprehensive manual 
(Miller et al., 1992).  This outlined specific examples for each of the 14 categories as 
well as providing overall guidance regarding severity scoring (Figure 6).   
 
0 - No Problem 
1 - Current mild problem or past significant problem 
2 - Moderate disability or morbidity/ requires "first line" therapy 
3 - Severe/constant significant disability/ "uncontrollable" chronic problems 
4 - Extremely Severe/immediate treatment required/end organ failure/severe 
impairment in function  
Figure 6: Guidance for severity scoring for the CIRS-G (Miller et al., 1992) 




2.9.2 Admission information 
On each admission, data was collected on one occasion regarding where the 
participant was admitted from and the level of support they were receiving along with 
the date and reason for admission.  The weight (kg), height (cm) and Malnutrition 
Universal Screening Tool (MUST) score were recorded if documented by the clinical 
team.  Recognised predisposing factors for delirium (Inouye et al., 2014) such as 
presence of visual or hearing impairment and whether they had a urinary catheter in 
situ prior to admission were documented along with whether patients were screened 
for delirium on admission.   
 
The Rockwood Clinical Frailty Score (Rockwood et al., 2005) and the Barthel Index 
of Activities of Daily Living were completed based on the history from the participant 
or their consultee in order to assess frailty and dependence in the weeks preceding 
hospital admission, prior to their current illness.  Although similar data was collected 
as part of the CFAS interview, these were performed up to 6 years prior to 
recruitment to DECIDE and so this data was collected to provide an up to date 
assessment of their level of independence.   
 
2.9.2.1 Frailty 
The Clinical Frailty Score (Rockwood et al., 2005) was selected as the measure of 
frailty to be used in this study due to the fact that it is quick and relatively simple to 
complete.  It consists of 9 descriptions ranging from “very fit” to “terminally ill” and is 
scored based on clinical judgement having spoken with the patient.  It does not 
require measurements of multiple domains like some of the more unwieldy frailty 
scores based on deficit counts but has been shown to be highly correlated with the 
Frailty Index (r=0.8) (Rockwood et al., 2005).   
 
2.9.2.2 Anti-cholinergic burden 
All regular medications taken by participants prior to admission were recorded.  
These were later rated based on the total number prescribed, indicating the degree 
of polypharmacy, and the anticholinergic burden, according to the Anticholinergic 
Burden Scale (Boustani et al., 2008).   
 
  




2.9.3 Daily review 
Participants were assessed daily, as far as possible, for the first five days by SR or a 
clinical research nurse.  From day 6, those with delirium continued to be seen daily 
until delirium resolution.   In the absence of delirium from day 6, or following 
resolution of delirium, participants were screened for delirium twice per week using a 
semi-structured interview including a modified version of the Delirium Observation 
and Screening Scale (Schuurmans et al., 2003).  If participants displayed any signs 
of delirium according to this, the full assessment described in Appendix B was 
performed to determine whether DSM-5 delirium was present (Figure 7).   
 
2.9.3.1 Delirium 
The primary exposure was delirium during hospital admission, ascertained 
prospectively using a standardised procedure based on DSM-5 criteria (American 
Psychiatric Association, 2013) (Table 5).  This assessment combined objective 
testing of the participant, lasting approximately ten minutes, with information gained 
from informants (usually nurses, next of kin and clinical records) and assessor’s 
judgement regarding subjective features.  Along with determining whether delirium 
was present according to DSM-5, these assessments enabled the recording of 
features of the delirium along with the development of new delirium.  It was possible 
to follow the natural history of the delirium in terms of any fluctuations, potential 
resolution and therefore estimate duration.  The subsequent development of delirium 
in previously non-delirious participants was also captured.  Delirium duration was 
recorded as the total number of days on which delirium was captured prospectively.   
The assessment was designed to combine multiple validated tools for delirium which 
enabled scores to be generated for a number of relevant variables.  The detailed 
recording of the phenomenological details of delirium provides unique information not 
previously collected at a population level.  All of the data collected contributed to the 
assessor’s overall judgement as to whether delirium was present or absent (Figure 
8).    
As well as detailed recording of the delirium itself, a number of other variables were 
recorded on a daily basis.  These are detailed below and were delirium severity, 
delirium motor subtype, level of alertness, attention, mobility and illness severity.  
Other factors that were also recorded on a daily basis were medication changes, 
ward moves, pain score, presence of glasses or hearing aids if required, last bowel 




movement as a proxy for constipation, fluid chart completion and fluid input as a 
proxy for dehydration, food chart completion, recent surgery, presence of a urinary 
catheter, physiotherapy input and whether delirium had been recognised and 
documented by the clinical team looking after the patient.  Completion of a FOCUS 
chart was also recorded.  This is a nursing assessment tool designed to be 
completed at least every two hours for all patients at risk of falls, pressure damage or 
delirium or with dementia.  It includes sections on footwear, orientation, constipation, 
whether the patient needs to go to the toilet, pain, whether they would like a drink, 
and comfort in order to prompt positional changes.   
 
These variables were carefully selected based on literature demonstrating these 
factors as either affecting the risk of developing delirium (Inouye et al., 2014) or as 
potential predictors of outcome following delirium (Jackson et al., 2016b).  As both 
reviews demonstrate, there is a lack of good quality studies in this area. Therefore, 
this study will be uniquely placed to explore more fully the role and effect size of 
confounding factors. The confounding effect of number of admissions and number of 





































Figure 7: A flowchart to represent the data collection plan for participants whilst 
inpatients 
Data collection continued until hospital discharge, the participant declined to 
participate, or they died.) 
 
Figure 8: Flowchart to represent the standardised approach used to diagnose 
delirium based on DSM 5 criteria for delirium (On next page)
Full daily review 
Full daily review 
Full daily review 
Full daily review 
Full daily review 
Day 
1 
Screen negative  
for delirium 
Screen positive  
       for delirium 
Full daily review No further action required on that day 
Full daily review until 
delirium resolution 
Screened for delirium 
on next review 
No delirium on day 5 Positive for delirium on Day 5 
Full daily review Screened for delirium Day 
6 + 



























Acute onset and/or fluctuation, check with nursing staff, NoK and check medical notes 
A: A disturbance in ATTENTION (i.e. reduced ability to direct, focus, sustain and shift 
attention) and AWARENESS (reduced orientation to the environment or even to oneself) 
B: Acute onset, represents a change from baseline and tends to fluctuate in severity during 
the course of the day 
Cognitive tests 
• MEMORY: WW2, Short and long term recall 
• ORIENTATION: Any abnormal orientation 
questions 
• VISUOSPATIAL: Will a stone float on water 
• LANGUAGE: 3 stage command, naming object 
 
Interview 
• LANGUAGE: fluency, 
comprehension and content of 
conversation 
• PERCEPTUAL DISTURBANCE: 
self-reported hallucinations and/or 
delusions 
C: An additional disturbance in cognition (NB: Low arousal states of acute onset should be 
recognised as indicating severe inattention and cognitive change, and hence delirium) 
D: Disturbances in A and C are not better explained by another pre-existing, established or 
evolving neurocognitive disorder and do not occur in a context of coma 
Informant 
No other pre-existing neurocognitive disorder 
Informant 
Ask medical team and check clinical records for another medical condition as a causal factor 
E: Evidence that the disturbance is a direct physiological consequence of another medical 
condition, substance intoxication or withdrawal or is due to multiple aetiologies 












Any behavioural signs that suggest inattention, lack 
of awareness and orientation such as distractibility, 
verbal perseverations, having to repeat the 
question. 
Questioning may include: Can you tell me what has been going 
on this morning? Do you know where you are? 
Arousal 
 
• m-RASS – any 
score other than 
0 











DSM-5 criteria Test to be performed or information needed 
A. Disturbance in attention (i.e., reduced ability to direct, 
focus, sustain, and shift attention) and awareness 
(reduced orientation to the environment). 
 
• Observations by the examiner during the interview (initiated by questioning such as “can you 
tell me what has been going on today?”) 
• Level of arousal measured using m-RASS and OSLA 
• Months of the year backwards 
• Digit span from MDAS 
B. The disturbance develops over a short period of time 
(usually hours to a few days), represents a change from 
baseline attention and awareness, and tends to fluctuate 
in severity during the course of a day. 
Acute onset and/or fluctuation obtained from informant history from nursing staff, next of kin and clinical 
notes  
C. An additional disturbance in cognition (e.g., memory 
deficit, disorientation, language, visuospatial ability, or 
perception). 
Impairment in any of the following domains: 
SHORT-TERM MEMORY: three item recall at three minutes 
LONG-TERM MEMORY: when did World War II end? 
ORIENTATION: 10 orientation questions from MDAS 
LANGUAGE: 3 stage command, naming an object and explain purpose of object along with fluency, 
comprehension and content of conversation 
VISUOSPATIAL: Will a stone float on water? 
PERCEPTUAL DISTURBANCE: evidence of illusions or hallucinations by collateral or direct 
observation/questioning 
D. The disturbances in criteria A and C are not explained 
by another pre-existing, established, or evolving 
neurocognitive disorder and do not occur in the context 
of a severely reduced level of arousal, such as coma. 
Information from history/chart/clinical examination 
E. There is evidence from the history, physical 
examination, or laboratory findings that the disturbance 
is a direct physiologic consequence of another medical 
condition, substance intoxication or withdrawal (i.e., 
because of a drug of abuse or to a medication), or 
exposure to a toxin or is because of multiple aetiologies. 
Information from history/chart/clinical examination 
 
Table 5: Standardised diagnostic algorithm for DSM-5 delirium (Richardson et al., 2017) 




2.9.3.2 Delirium severity 
Delirium severity was calculated based upon the Memorial Delirium Assessment 
Scale (MDAS) (Breitbart et al., 1997).  The MDAS is a brief, physician-rated scale 
designed specifically for quantifying delirium severity among a medically ill population 
(Breitbart et al., 1997).  The ten-items included in the MDAS are based upon the 
diagnostic criteria for delirium in DSM-IV (American Psychiatric Association, 1994) 
and are rated by integrating behavioural observations and objective cognitive testing.  
Each item is rated from 0 to 3 based upon descriptions reflecting the severity or 
intensity of the symptom.   
 
Although originally designed for use in inpatients with Acquired Immunodeficiency 
Syndrome (AIDS) and cancer (Breitbart et al., 1997), the MDAS has been 
successfully validated in people over 65 years (Marcantonio et al., 2002).  Validation 
studies have also demonstrated that, at a cut-off for maximum MDAS score during 
admission of 9, the MDAS can also successfully identify delirium (sensitivity of 88%, 
specificity of 91%) (Marcantonio et al., 2002).  Despite this, the MDAS was built into 
the overall assessment of participants and not used as a primary measure of 
presence or absence of delirium due to the fact that it does not include items for 
temporal onset or fluctuation of symptoms needed to diagnose delirium according 
DSM 5 (American Psychiatric Association, 2013).   
 
Unlike other measures of delirium severity such as the Delirium Rating Scale (DRS-
R98) (Trzepacz et al., 2001), the MDAS was designed for repeated assessment by 
clinicians and requires less cognitive testing.  This made it advantageous for the 
purpose of this study whereby we did not want to over-burden participants on a daily 
basis with too many questions.  The MDAS and the DRS-R98 have previously shown 
substantial agreement in a palliative care setting (O'Sullivan et al., 2015).   
 
2.9.3.3 Delirium motor subtype 
Motor subtype was defined based upon the Delirium Motor Subtype Scale (Meagher 
et al., 2014a).  Previous work in highly selected populations has shown that 
hypoactive delirium is associated with worse outcomes in terms of mortality and 
institutionalisation (Jackson et al., 2016).  In order to avoid unnecessary repetition 
within the data collection proforma, the DMSS was derived from item 9 of the MDAS 
(Breitbart et al., 1997).   




2.9.3.4 Level of alertness/arousal 
Level of alertness was recorded using the Observational Scale of Level of Arousal 
(OSLA) (Tieges et al., 2013), the modified Richmond Agitation and Sedation Score 
(Chester et al., 2012) and the Glasgow Coma Scale (GCS).   
 
The OSLA was designed by geriatricians specifically for use in delirium and provides 
a structured approach for the detailed recording of the features of deranged level of 
arousal.  It consists of 4 domains: eye opening, eye contact, posture and movement 
with higher scores indicating an abnormal level of arousal.  The OSLA is appealing 
as it is brief, observational, and does not require formal testing of cognition.  
Therefore, it was possible to record an OSLA score for all participants, even if they 
were unable to complete any of the cognitive testing.  This inclusivity is relatively 
unique to the OSLA.  In validation studies, abnormal level of arousal, as measured by 
the OSLA, has been shown to be strongly associated with the presence of delirium 
(area under the receiver operating characteristic curve was 0.89 [CI: 0.81-0.97), with 
a sensitivity of 0.87 and a specificity of 0.81) (Tieges et al., 2013).     
 
The Richmond Agitation and Sedation Scale (RASS) is used mainly in mechanically 
ventilated intensive care patients to measure their agitation or level of alertness to 
avoid over and under-sedation (Sessler et al., 2002).  RASS scores have been 
shown to be correlated with onset of delirium (Ely et al., 2003).  However, a 
disadvantage of using the RASS is its limited attention assessment.  The modified-
RASS aimed to build on this limitation by improving the assessment of attention by 
including a brief, open-ended question to be asked prior to scoring (”Describe how 
you are feeling today”) (Chester et al., 2012).  The modified-RASS was designed for 
use in a general hospital setting for serial assessments and, with a cut-off of any 
score other than 0, has demonstrated a sensitivity of 74% and specificity of 92% for 
delirium (Chester et al., 2012).  The m-RASS provides either a positive or a negative 
score, which is informative of subtype, unlike the OSLA, which is non-directional.   
 
The Glasgow Coma Scale (Teasdale and Jennett, 1974) was recorded due to the 
fact that it forms part of most of the illness severity measures which will be discussed 
shortly.   
  




2.9.3.5 Measures of attention 
A patient’s inability to focus, sustain and shift attention toward environmental stimuli 
is relatively specific to delirium (Brown et al., 2011b, Tieges et al., 2013).  Multiple 
tests of attention have been studied in the context of delirium diagnosis (Meagher et 
al., 2010, Brown et al., 2011a, Tieges et al., 2014, Tieges et al., 2015).  However, the 
best methods for measuring inattention in delirium are not known.  A major problem 
is that many of the existing tools are not specific for delirium because attentional 
deficits may already be present if someone has dementia, particularly when it is 
severe, regardless of whether they have delirium superimposed on their dementia.  
Many of the tools available currently also test multiple cognitive domains alongside 
attention and so may also be abnormal in someone with dementia due to their 
cognitive impairment rather than due to inattention.       
In this study, several measures of attention were included.  The MDAS uses digit 
span to test attention along with an overall evaluation of attention based on the 
assessor’s judgement.  The months of the year backwards test was also included.  
The month reached was recorded along with a score: 0 equated to being untestable, 
1 equated to participants who started but did not reach June and a score of 2 was 
given if participants reached June or better.  This was in line with the scoring used for 
the widely validated 4 A’s Test (4AT) (Bellelli et al., 2014).      
 
For those unable to complete these tests, 3 other measures of attention were also 
included.  These were days of the week backwards, counting backwards from 20 to 1 
and a test of vigilance.  To test vigilant attention, participants signalled each time an 
“A” was heard when the sequence of ten consecutive letters “S-A-V-E-A-H-A-A-R-T” 
was read out, each letter 3 seconds apart.  A failure to complete the test was defined 
as when a patient failed to signal on the letter “A” or when a patient signalled on any 
letter other than “A”.  A test of vigilant attention is appealing as it is simple enough to 
remain possible even for those with dementia (Leonard et al., 2016).  This test is 
included as the test for attention in the CAM-ICU (Ely et al., 2001), a widely used 








2.9.3.6 Illness severity 
A major confounding factor that has not previously been explored is illness severity.  
Illness severity was recorded during admission using recognised illness severity 
measures (APACHE II (Knaus et al., 1985)/SOFA (Vincent et al., 1996)/SAPS II (Le 
Gall et al., 1993)).  The data required to complete these measures was collected 
when participants were seen as part of the ‘daily review’.  Due to the fact that these 
scores were designed for use in the intensive care unit, they include variables that 
are not commonly recorded in general medical patients including pH and arterial 
oxygen concentrations.  Therefore, a modified total score was used which does not 
include these variables.   
 
Due to the limitations of these illness severity markers previously discussed, the 
utility of the Hierarchical Assessment of Balance And Mobility (HABAM) (MacKnight 
and Rockwood, 1995) as a surrogate marker for illness severity and recovery along 
with delirium development/resolution was also explored. 
 
2.9.3.7 Hierarchical Assessment of Balance and Mobility 
The HABAM consists of three domains (balance, transfers, and mobility) which are 
scored based on observation of the patient with items in each domain arranged 
hierarchically to provide a graphic and rapid assessment.  The HABAM overcomes 
the floor effect associated with other measures such as the Tinetti Gait and Balance 
Scale (Tinetti, 1986) and Timed Up-and-Go test (Podsiadlo and Richardson, 1991), 
in those unable to walk, by including clinically relevant changes such as being 
completely unable to move to being able to roll over.   
 
The HABAM has been shown to be a valid, reliable, and responsive assessment of 
balance, transfers, and mobility designed to be used by clinicians at the bedside.  It 
was validated in 167 frail older adults in medical and geriatric wards, ambulatory 
care, emergency department and home visits and showed good inter-rater reliability 
(0.92) and test-re-test reliability (0.91) (Rockwood et al., 2008).    
 
  




2.9.4 Delirium recognition 
Documentation of the diagnosis of delirium by the clinical team looking after the 
patient was also recorded.  Previous work has shown that delirium is under-
recognised and poorly documented (Milisen et al., 2002).  Patients in whom their 
delirium was missed have also been shown to have worse outcomes (Kakuma et al., 
2003).   
 
2.9.5 Validated tool for retrospective delirium ascertainment 
If it was not possible to review participants prospectively at any particular time point, 
due to illness, refusal or study capacity, a validated tool was used to retrospectively 
review the medical records for a diagnosis of delirium (Kuhn et al., 2014). 
 
2.9.6 End of data collection 
Recruitment of hospital attendees stopped after 12 months on the 5th January 2017.   
 
In those participants in whom a diagnosis of delirium was not possible or was 
contentious, vignettes were generated and sent to an expert consensus panel (LA, 
SP, and DD) consisting of experienced clinicians with considerable familiarity with 
diagnosing delirium.  The vignettes contained a complete copy of the data collection 
forms for the participant along with a summary of this data following entry onto the 
study database.  It also contained any information collected retrospectively regarding 
cognition from the medical records as described in section 2.9.5.   
 
Two members of the expert panel (LA, DD) independently reviewed each case and if 
they disagreed, a third member (SP) reviewed the case and a majority decision was 
applied. The panel were tasked with determining whether delirium was present or 
absent.  The use of a consensus panel enabled an objective approach.  Participants 
were identified only by their unique study identifier and were therefore anonymised.   
  




2.10 Follow up interviews 
All participants recruited in hospital, with and without delirium, were invited for follow 
up 12 months after their most recent hospital discharge.  Follow up consisted of a 
home visit to complete the same interview participants had for CFAS II wave II.  This 
included the Geriatric Mental State-Automated Geriatric Examination for Computer 
Assisted Taxonomy (GMS-AGECAT) which provides a quantitative measure of 
cognition, including a CAMCOG and MMSE, along with dementia status and other 
relevant data such as place of residence and an assessment of physical function.  As 
was the protocol for CFAS II, participants were not informed of their results from the 
interview. 
 
The Informant Assessment of Geriatric Delirium Scale (I-AGeD) (Rhodius-Meester et 
al., 2013) was used to explore whether there had been any further episodes of 
delirium between their discharge from hospital and the follow up interview.  This was 
completed by a next of kin in person at the follow up interview if available or by 
telephone with the permission of the participant.  The I-AGeD was designed to be 
used on admission to hospital but was modified to request information from “over the 
past year” in order to cover the study period from 5th January 2016 to 5th January 
2017.   
 
A control group of non-hospital attendees during the study period were sampled from 
the CFAS II-Newcastle cohort on a 1:2 basis.  Stratified sampling was used to match 
1 control to every 2 participants already recruited to DECIDE by gender, age and 
years of education.  To do this, the recruited participants were divided into 12 groups 
according to their age, gender and years of education.  The eligible control 
population were then divided into the same 12 groups.  4 to 1 oversampling was 
used initially.  A random number generator was used to assign each of the sampled 
controls a random number.  Participants with an even number were then invited to 
participate following checking to ensure that they had not been admitted to hospital 
or died.  Once all of these participants had either been approached or excluded due 
to admission to hospital or death, further controls were selected from the remaining 
sampled participants by selecting those with the lowest random numbers in the 
groups still requiring matched controls.   
 




Absence of a history of delirium was ascertained via an interview based on the 
Informant Assessment of Geriatric Delirium Scale (I-AGeD) (Rhodius-Meester et al., 
2013) completed by a next of kin in person at the follow up interview if available or by 
telephone with the permission of the participant.  In order to assess the diagnostic 
test accuracy of the I-AGeD in this setting, completion was attempted for all 
participants in the DECIDE study, and not limited to just the controls.   
 
This control group provided a comparator to those admitted to hospital to determine 
the effect of hospital admission in itself on cognitive decline. 
2.11 Training of researchers 
All data collection was carried out by the chief investigator (SR) and a part time 
research nurse.  The chief investigator is a trainee in Older People’s Medicine with 
experience in the detection of delirium in acute hospitals whilst working as a doctor.  
The research nurse also had previous experience of working with people with 
delirium on the intensive care unit where she worked as a nurse prior to starting as a 
research nurse.   
 
At the start of the study, prior to the commencement of data collection, both 
completed a comprehensive programme of training in the assessment of delirium in a 
research setting and familiarisation with the data collection proformas.  Educational 
resources were used, designed by Edinburgh University, to learn about the basics of 
delirium assessments.  A Standard Operating Procedure was also devised for use 
alongside the data collection proformas.   
 
The chief investigator and the research nurse travelled to Birmingham University to 
meet with Dr Thomas Jackson to receive training in the assessment of patients with 
delirium.  The day consisted of sessions on how to assess for the core features of 
delirium including awareness, attention, cognition and onset.  The assessment of 
participants who were difficult to evaluate due to drowsiness, for example, were also 
discussed.  Visits to the wards to observe the assessment of patients with delirium 
were completed and videos were used to practice scoring patients in a controlled 
environment.   
 




Following this visit, time was spent watching online videos as well as specially 
recorded training videos and assessing patients using the data collection forms.  
These data collection forms were also piloted on the wards in the hospital.  
 
At random time-points throughout the study, joint assessments of a sample of 
participants were completed to monitor inter-rater reliability and to optimise 
consistency between assessors.  
 
Training to deliver the standardised computerised interview was identical to that 
received by staff working on previous waves of the study.  A week-long course run by 
the team based at Cambridge University was completed, with follow-up practice until 
each interviewer achieved the necessary quality standards.  There was also ongoing 
quality control which involved audio recording interviews with consenting participants 
for review by the team at Cambridge University (Matthews et al., 2013).   
2.12 Data Handling and Confidentiality   
Data was handled, computerised and stored in accordance with the Data Protection 
Act 1998.  No participant identifiable data left the study site.  Participants were 
allocated a unique study identifier which was used on all data stored in order to 
ensure anonymity.  Caldicott approval was granted.  Personal data was regarded as 
strictly confidential.  All study records, including the consent forms, and investigator 
site files were kept in a locked filing cabinet with restricted access.   
2.13 Ethical approvals 
The study design, protocol and paperwork were reviewed and given favourable 
opinion by the Newcastle and North Tyneside 2 Regional Ethics Committee (REC 
reference: 15/NE/0353).   
2.14 Power calculations  
We aimed to detect a clinically and statistically significant difference in the annual 
decrease in the total CAMCOG (total score 107), between 6 points in delirium 
participants and 3 points in participants without delirium.  Assuming that 10% of the 
cohort (the most conservative end of the range) was a delirium case and that the 
standard deviation of the decrease in CAMCOG is 2.7 points (Cullum et al., 2000), 




then in order to detect the desired difference (2-fold) in the CAMCOG with 90% 
power, using a two-sided test at the 5% level, 10 participants with delirium at the time 
of admission to hospital and 90 participants without delirium would be needed, i.e. a 
total of 100 participants.  The analysis would additionally allow for other factors using 
a regression approach, rather than simply comparing how the change in CAMCOG 
from admission to follow-up differs between the two groups.  Also, whilst the 
calculation assumes complete data have been collected for all participants, the 
analysis will explore the possibility of incorporating participants with missing data.  
The above calculations are based on a very conservative prevalence of delirium of 
10%.  If, for example, the prevalence was 20%, then a total of 55 participants (11 
with delirium, 44 without) would be required, based on the assumptions outlined 
above. 
 
By applying the expected number of admissions per age group, based on best 
available data (Blunt et al., 2010), to the number of people within these age groups 
remaining in the CFAS II-Newcastle cohort, it was possible to estimate that 450 
people would be admitted during the year long study period.   
2.15 Statistical analysis 
All statistical analysis was performed on STATA Version 15.  All graphs, unless 
otherwise stated, were created using Microsoft Excel 2013. 
2.15.1 Recruitment, admission rates and demographics 
All continuous variables were checked for normality by plotting in histograms and 
assessing the normality of the distribution.  These graphs, generated on STATA 
version 15, are displayed where relevant.  Between groups differences for baseline 
characteristics were checked using an independent t-test, Kruskall-Wallis test or chi-
squared test depending on whether the data were continuous or categorical, normal 
or non-normally distributed.  For clarity, the statistical test used is stated in the results 
tables below the p value obtained.  Multiple logistic regression analysis was used to 
determine which of the variables were independently associated with admission. 
2.15.2 Delirium incidence 
As above, between groups differences in characteristics were checked using an 
independent t-test, Kruskall-Wallis test or chi-squared test depending on whether the 
data were continuous or categorical, normal or non-normally distributed.  The 




statistical test used is stated in the results table below the p value obtained.  Multiple 
logistic regression analysis was used to determine which of the variables were 
independently associated with delirium.   
In cases of diagnostic uncertainty, the diagnosis of delirium was determined by a 
consensus panel as described in section 2.9.5.  When there was disagreement in the 
diagnosis between the two expert assessors, a third expect panel member was 
required to create a majority decision.  Sensitivity analysis was performed to explore 
whether these cases impacted on the results obtained in statistical analysis.  This 
was done by performing all subsequent analysis with these cases and then without 
these cases.  The results of these sensitivity analyses are recorded.   
2.15.3 Outcomes at 1 year 
The primary aim of the study was to measure the effect on cognition of an episode of 
delirium, independent of baseline cognition and illness severity.   
The CAMCOG was used as the primary measure of global cognitive status when 
examining the effect of delirium as the exposure.  Total MMSE score at follow up was 
also evaluated as a measure of cognitive status.  This is shorter than the CAMCOG 
and consequently, would be expected to be completed by a greater proportion of 
participants, even if very cognitively impaired.  The binary outcome measure of 
dementia yes or no at follow up according to the AGECAT was also considered.   
 
In order to evaluate the contribution of delirium to cognitive outcomes at follow up 
(measured using CAMCOG, MMSE and AGECAT diagnosis), regression analysis 
was performed.  Relevant confounders including age, years of education, gender, 
illness severity, frailty, baseline cognition, comorbidities and time between wave 2 
and follow up interviews were included in the regression analysis alongside delirium 
status.   
 
Death prior to the follow up interview and new institutionalisation were also 
considered as outcomes and regression analysis, as described above, was 
performed to evaluate the independent contribution of delirium.   
 
To avoid the survivor effect associated with evaluating CAMCOG score alone as an 
outcome, a binary ‘poor outcome’ was considered to be death, institutionalisation or 




new dementia at follow up interview.  Regression analysis was performed to evaluate 
the independent contribution of delirium. 
 
The outcome measures explored are summarised in Table 6 along with whether the 
variable was continuous or binary.  Multiple regression analysis was used for 
continuous outcome measures and logistic regression analysis was used for binary 
outcome measures. 
 
Outcome measure Type of data 
Total CAMCOG score at follow up interview Continuous 
Total MMSE score at follow up interview Continuous 
AGECAT diagnosis of dementia Binary 
Death prior to follow up interview Binary 
Institutionalisation Binary 
Poor outcome – new AGECAT diagnosis of dementia OR death prior to 
follow up interview OR institutionalisation 
Binary 
Table 6: Outcome measures to be explored in analysis 
 
The sensitivity of the results to patterns of missing data and methods for accounting 
for this were also explored.  In general, due to the small amount of missing data, 
participants with missing data were excluded from analysis.  Where this occurred, the 
reasons for the missing data were investigated and any specific patterns were 
detailed in the discussion. 
 
Sensitivity analysis was performed, as described previously in Section 2.15.2, to 
explore whether the more challenging diagnostic cases impacted on the results 
obtained in statistical analysis. 
 
Regression analysis was also used to explore the impact of hospital admission on 
these outcomes by comparing outcome data in those who were admitted during the 




study period with the controls sampled who were not admitted to hospital during the 
study period.  
 
The diagnostic accuracy of the I-AGeD for ascertaining a retrospective diagnosis of 
delirium over the preceding year was evaluated using the diagnosis of delirium 
obtained prospectively for the DECIDE study as a gold standard.  A receiver 
operating characteristic curve was generated for the I-AGeD along with a calculation 
of the area under the curve (AUROC) and the best cut-off determined.   
2.15.4 Predictors of poor outcomes 
Using regression analysis as described above, with the outcomes listed in Table 6, it 
was possible to explore the predictive value of peak delirium severity, delirium motor 
subtype, delirium duration, number of episodes of delirium and presence or absence 
of perceptual disturbances whilst controlling for the confounding effects of age, years 
of education, gender, illness severity, frailty, baseline cognition, comorbidities and 
time between wave 2 and follow up interviews. 
 
The overall approach is novel because no previous delirium ascertainment studies 
have been nested within an existing, well-characterised cohort allowing baseline 
characteristics to be controlled for in the final analysis.  Assistance with data analysis 
was sought from collaborators who have experience in this field and have also 
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Chapter 3: Results – Demographics 
3.1 Recruitment 
Of the 2,582 participants originally interviewed in wave 1 of the CFAS II-Newcastle 
cohort, 1751 were re-interviewed at wave 2 (67.1%).  Of these, 1328 participants 
were surviving and non-objecting at the start of the DECIDE study in January 2016 


























Figure 9: Flowchart showing the number of CFAS II - Newcastle participants 
interviewed at Wave I and Wave II and eligible for DECIDE 
WAVE II 
1751 participants interviewed 
1328 surviving, non-objecting 
participants eligible for DECIDE 
WAVE I 
2582 participants interviewed 
February 2009 – November 2011 
August 2011 – December 2013 
5th January 2016 




1328 RAPAs (recurring admission patient alerts), or electronic flags, were applied to 
the medical records of surviving, non-objecting CFAS II-Newcastle participants on 5th 
January 2016.  Those participants who were inpatients on the day that the flags were 
applied were not approached at this time.  Only newly admitted participants from 5th 
January 2016 were approached and invited to take part.  For participants to activate 
a RAPA alert, they had to be admitted to a ward within the hospital.  Therefore, 
attendances to Accident and Emergency did not trigger an alert unless they were 
admitted to the observation ward which forms part of Accident and Emergency.  
Patients are often held here whilst they await a bed or review by the multi-disciplinary 
team regarding safety for discharge. 
 
During the year of hospital ascertainment, between 5th January 2016 and 5th January 
2017, 363 (27.3%) CFAS-II Newcastle participants were admitted to the Newcastle 
upon Tyne Hospitals NHS Foundation Trust (Figure 10).  83 of these participants did 
not fulfil the inclusion criteria: 60 were admitted for less than 24 hours, 12 were not 
approached as it was felt to be inappropriate due to their diagnosis, 6 died prior to 
being approached and 5 were barrier nursed throughout their admission due to 
infections. 
 
Of the remaining 280 eligible participants, 205 were recruited to the study (73.2%).  
75 were not recruited: 49 declined, 12 had no capacity and no next of kin to act as a 
consultee and 14 were not approached by the study team and therefore missed. 
 
  




































Figure 10: DECIDE recruitment flowchart  
363 participants admitted  
05/01/16 – 05/01/17 (27.3%) 




• 60 admitted for <24 hours 
• 12 inappropriate due to diagnosis 
• 6 died 
• 5 barrier nursed until discharge 
280 eligible 
75 not recruited 
• 49 declined 
• 12 no capacity and no next of kin 
• 14 not approached 




3.2 CFAS II-Newcastle participants admitted in 2016 
3.2.1 Admission rates 
Between 5th January 2016 and the 5th January 2017, there were 607 admissions by 
363 participants.  Of these admissions, 476 were for a duration of over 24 hours 



























476 admissions >24 
hours 
1328 participants flagged 




The RAPA was active for the study during 2016 and 2017 so it is possible to 
compare the rates of admissions per month between the two years (Table 7).  By 
dividing the number of admissions per month by the number of days in the particular 
month that were studied, it is possible to calculate the mean number of admissions 
per day each month (Figure 12). 
 
 
Figure 12: Mean number of admissions per day by month  





Number of days 
assessed in 
month in 2016 
Number of 
admissions per 
month in 2016 
Admissions per day 
2016 
Number of days 
assessed in 
month in 2017 
Number of 
admissions per 
month in 2017 
Admissions per day 
2017 
January 27 47 1.74 31 49 1.58 
February 29 49 1.69 28 48 1.71 
March 31 55 1.77 31 63 2.03 
April 30 56 1.87 30 38 1.27 
May 31 62 2.00 31 45 1.45 
June 30 64 2.13 30 47 1.57 
July 31 58 1.87 31 62 2.00 
August 31 43 1.39 31 52 1.68 
September 30 45 1.50 30 45 1.50 
October 31 48 1.55 31 35 1.13 
November 30 35 1.17 30 48 1.60 
December 31 41 1.32 31 60 1.94 
Table 7: Flowchart of admissions 05/01/2016 – 31/12/17 
NB: Due to the fact that the flags were applied on 5th January 2016, January 2016 contained fewer days studied than January 2017.  
The total number of admissions in 2016 according to the table above is 603, 4 less than the total given previously in Figure 11.  This 
is due to the fact that the total number of admissions during the year study period ended on the 5th January 2017, and so included a 
further 4 admissions, while the table above included these 4 admissions in the January 2017 data. 




3.2.2 Demographics  
When comparing those who were admitted during the study period from 5th January 
2016 to 5th January 2017 (n=363) to those who were not (n=965), those who were 
admitted were significantly older, more cognitively impaired, more likely to be living in 
24 hour care, more likely to be from an unskilled, partly skilled or skilled manual 
social class household, more disabled and with 10 or fewer years of full time 




















Age at wave 2 interview in years  
(mean, SD) 
 




Accommodation at wave 2  
(% living in 24-hour care) 
 




Social class  
(% in social class IIIM (skilled 
manual occupations), IV (partly-












Modified Townsend disability 
score (% with more functional 











Cognition at wave 2 - CAMCOG 
total score (mean, SD)  
 
86.50 +/- 9.89 
 
N=339 






















Table 8: Characteristics of CFAS II-Newcastle participants admitted to hospital 
compared to those not admitted during the study period using baseline data from 
CFAS II-Newcastle (variables with a significant difference demonstrated shown in 
bold) 




Multiple logistic regression analysis was used to determine which (if any) of the 
variables shown in Table 8 were independently associated with admission.  In this 
analysis, age, baseline cognition measured using CAMCOG and functional 
incapacity, according to the modified Townsend disability score, remained statistically 
significant predictors of admission when adjusting for the other variables (Table 9).  
This equates to an increased risk of admission to hospital of 5% for each year older 
you are or a decreased risk of admission to hospital of 4% for every additional point 








Female  0.936 0.704 – 1.245 0.650 
Age at wave 2 interview (years)  1.047 1.023 – 1.071 0.000 
Institutionalised at wave 2 interview 1.554 0.259 – 9.312 0.629 
Social class IIIM, IV or V 1.180 0.872 – 1.598 0.283 
Modified Townsend disability score 11-18 
(more functional incapacity) 
1.818 1.156 – 2.859 0.010 
Cognition at wave 2 interview measured using 
total CAMCOG score (points) 
0.960 0.943 – 0.978 0.000 
≤10 years in full time education 1.138 0.834 – 1.552 0.415 
Table 9: Results of regression analysis exploring variables which independently 
predicted admission during the study period  
  




3.3 DECIDE participants recruited in hospital 
3.3.1 Admission rates  
As per Figure 10, 205 participants were recruited to the DECIDE study on admission 
to hospital.  96 of these participants were readmitted during the study period (46.8%).  

















Table 10: Number of admissions for DECIDE participants during the study period 
from 5th January 2016 to 5th January 2017 
 
Mean length of stay overall was 10 days with a range from 0 to 100 days.  The mean 
length of stay per admission is shown in Table 11. 
 
  






Table 11: Mean length of stay by admission for the 205 participants recruited to DECIDE in hospital during the study period from 5th 
January 2016 to 5th January 2017 
  
 
Admission number 1 2 3 4 5 6 7 8 9 10 
Number of 
participants 
205 96 41 22 14 6 4 1 1 1 
Total number of 
inpatient days 
2097 835 326 162 148 124 114 8 16 22 
Mean length of stay 
(days) 
10 9 8 7 11 21 29 8 16 22 




3.3.2 Demographics  
205 participants were recruited to the DECIDE study during their inpatient stays in 
2016.  These participants had a mean age of 82 years ranging from 69 to 99 years 
(Figure 13).  109 of the 205 participants recruited were female (53.2%).   
 
Mean total CIRS-G score, a measure of comorbidity, for the 205 participants was 
8.57 ranging from 0 to 22 (Figure 14).  Mean Rockwood Clinical Frailty Score for the 
first admission during the study period was 4.25 (Figure 15).  Mean total Barthel 
Index of Activities of Daily Living Score for the first admission during the study period 




Figure 13: Histogram representing age distribution of DECIDE participants recruited 
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Figure 14: Histogram representing total CIRS-G score for DECIDE participants 
recruited in hospital (drawn using STATA Version 15) 
 
On their first admission during the study period, 12 participants (5.85%) lived in 24 
hour care.  Of the remaining 193 participants, 104 lived in a house, 47 in a bungalow, 
27 in a flat and 15 in sheltered accommodation.  15 of those who were not in 24-hour 
care had formal care packages (7.77%). 
 
44 of the 205 participants were recruited via a consultee (21%) because they lacked 
the capacity at the time of admission to take part in the study.  21 participants had a 
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Figure 15: Histogram representing total Rockwood Clinical Frailty Score on first 
admission during the study period 
 
  
Figure 16: Histogram representing total Barthel Index of Activities of Daily Living 











































Of the 363 participants admitted to hospital during the study period, 205 were 
recruited to DECIDE.  158 participants were not recruited, for reasons as detailed in 
Figure 10.  Due to the fact that these people are all part of CFAS II-Newcastle, it was 
possible to compare the baseline characteristics of those recruited with those not 
recruited to ensure there was no sampling bias.  Table 12 shows that there were no 
significant differences in baseline characteristics between the two groups.   
 















58.23 53.17 No (p=0.337) 
 
(Chi-squared) 























Accommodation at wave 2 
interview (% living in 24-hour 
care) 
 
3.16 1.46 No (p=0.274) 
 
(Chi-squared) 
Social class at wave 1  










Modified Townsend disability 
score (% with more functional 










Cognition at wave 2 interview - 















Table 12: Demographics of CFAS II-Newcastle participants admitted to hospital but 
not recruited compared to those who were recruited to DECIDE during the study 
period using baseline data from CFAS II-Newcastle 
  





3.5.1 Sampling and recruitment 
The 965 CFAS II-Newcastle participants who were flagged at the start of the study 
and had no admissions to hospital during the study period were eligible as controls.  
A further 33 were admitted to hospital between the end of the study period and the 
day of sampling and these participants were also excluded.  A further 5 people were 
removed from the list of potential controls due to the fact that their GP had informed 
the study team that they had died.  The remaining 927 CFAS II-Newcastle 
participants were eligible as controls (Figure 17).   
 
The 4 to 1 oversampling used initially resulted in 406 controls being sampled from 
the 927 eligible participants.  202 of these participants were assigned an even 
number and therefore approached or excluded due to having been admitted since 
sampling or having died since sampling.  Further controls were selected from the 
remaining participants from the sample of 406 by selecting those with the lowest 
random numbers in the groups still requiring matched controls.   
 
In total, 187 control participants were approached and invited to be interviewed and 
101 controls were recruited.  During the interview with one of the control participants, 
it became apparent that they had been admitted to hospital just prior to the interview 












































Figure 17: Recruitment flowchart for controls 
965 eligible as controls at end of 
study period 
 
101 controls recruited 
38 participants excluded 
• 33 admitted up until the point of 
sampling 
• 5 removed as informed by GP that they 
had died 
 
927 eligible as controls on day of 
sampling 
 
406 controls sampled 
187 approached and invited to 
be interviewed 
• 2 admitted up until the point of invite for 
interview 
• 3 moved out of region 
• 64 declined 
• 17 unable to contact 
• 16 admitted to hospital up until the point 
of invite for interview 
• 14 died between sampling and invite for 
interview 
• 189 not approached as recruitment 
complete 
• 1 participant excluded as admitted to 
hospital prior to interview 
100 controls eligible 




3.5.2 Demographics of the control population 
Table 13 compares the control population to the DECIDE participants recruited in 
hospital.  The control population is matched, as intended, for age, gender and years 
of education.  The DECIDE participants recruited in hospital had significantly worse 
baseline cognition and were significantly more functionally incapacitated according to 
















55.00% 53.17% No (p=0.764) 
 
(Chi-squared) 










≤10 years in full time education (%) 
 
 
71.00% 71.22% No (p=0.968) 
 
(Chi-squared) 
Accommodation at wave 2 interview 
(% living in 24-hour care) 
 
0.00% 1.46% No (p=0.224) 
 
(Chi-squared) 
Social class  










Modified Townsend disability score 
at wave 2 (% with more functional 










Cognition at wave 2 - CAMCOG 















Table 13: Comparison of demographics of controls recruited compared to DECIDE 
participants recruited in hospital 
 
 




Chapter 4: Results – Delirium incidence 
4.1 Incidence of delirium 
82 of the 205 participants recruited to the DECIDE study had delirium at some point 
during their time as an inpatient during the study period between 5th January 2016 
and 5th January 2017.  This equates to a delirium incidence of 40%. 
 
Compared to those who did not develop delirium, those who did develop delirium 
were older, were more likely to be from an unskilled or manual labour household, 
were more functionally impaired, had more co-morbidities, were frailer, were more 
likely to have “dementia” documented in their medical records and were more 
cognitively impaired when last interviewed as part of CFAS II (Table 14).   
 
Multiple logistic regression analysis was used to determine which (if any) of the 
variables shown in Table 14 were independently associated with the development of 
delirium during the study period (Table 15).  In this analysis, age and cognition at 
wave 2 interview measured using total MMSE score remained statistically significant 
predictors of delirium when adjusting for the other variables.  The analysis showed 
that for each year older you are, the risk of delirium increased by 9% (OR 1.093 [CI: 
1.029 – 1.161]).  It also showed that for every point gained on the MMSE, your risk of 
delirium reduced by 5% (OR 0.952 (CI: 0.912 – 0.995)).    
 
In Table 15, the number of participants living in 24 hour care was not included in 
logistic regression analysis because the proportion of people in both groups who 
were institutionalised was very small. 
 


















48.78% 56.10% No 
(p=0.304) 
Chi-squared 
Age when recruited to DECIDE  
(mean, SD) 
 
84.71 +/- 6.52 80.27 +/- 5.88 Yes 
(p<0.000) 
Independent t-test 
Accommodation when recruited to DECIDE (% living in 24-hour 
care) 
 
7.32% 4.88% No 
(p=0.466) 
Chi-squared 
Social class at wave 1  
(% in social class IIIM (skilled manual occupations), IV (partly-










Modified Townsend disability score at wave 2 interview (% with 








CIRS-G total (mean, SD) 
 
10.05 +/- 4.22 7.56 +/- 4.13 Yes 
(p<0.000) 
Independent t-test 
Cognition at wave 2 - CAMCOG total score (mean, SD)  
 
82.10 +/- 11.34 
(n = 78) 
89.74 +/- 6.99 





MMSE wave 2 (mean, SD) 
 




≤10 years in full time education (%) 
 
78.05% 66.67% No 
(p=0.078) 
Chi-squared 
Dementia documented in medical records (%) 20.73% 3.25% Yes 
(p<0.000) 
Chi-squared 
Rockwood Clinical Frailty Score (mean, SD) 4.94 +/- 1.20 3.80 +/- 1.40 Yes 
(p<0.000) 
Independent t-test 
Table 14: Comparison of demographic data for DECIDE participants recruited in hospital who developed delirium during the study 
period with those who did not develop delirium during this time (variables reaching statistical significance shown in bold).  












Gender (female) 0.874 0.423 – 1.806 0.717 
Age (per year) 1.093 1.029 – 1.161 0.004 
In social class IIIM (skilled manual occupations), IV 
(partly-skilled occupations) or V (unskilled 
occupations) at wave 1 
1.795 0.851 – 3.784 0.124 
More functional incapacity (score 11-18) according 
to modified Townsend disability score  
1.945 0.703 – 5.378 0.200 
Total CIRS-G score (per point) 1.093 0.996 – 1.201 0.062 
Clinical Frailty Score (per point) 1.151 0.827 – 1.603 0.405 
≤10 years in full time education 1.467 0.638 – 3.374 0.367 
Cognition at wave 2 interview measured using 
total MMSE (per point) 
0.952 0.912 – 0.995 0.027 
Table 15: Results of logistic regression analysis exploring baseline characteristics 
which independently predict delirium.   
  




4.1.1 Diagnostic uncertainty 
In 18 of the 82 cases of delirium, the diagnosis was determined by a consensus 
panel due to the fact that the diagnosis was not clear during the prospective 
assessments.  The panel consisted of 2 experts (LA and DD) who reviewed all of the 
available data, both prospective data collected at the time of the study by reviewing 
the data collection forms, and retrospective data recorded from the medical records 
using a validated tool (Kuhn et al., 2014).  The two assessors were blinded to each 
other’s decisions.   
 
In 4 cases, there was disagreement in the decision and so a third expert panel 
member (SP) was required to create a majority decision.  This panel member was 
also blinded to the previous assessors’ decisions and had access to the same 
prospective and retrospective data.  Sensitivity analyses were carried out by 
performing all subsequent analysis with and without these cases to explore whether 
these cases impacted on the results obtained.     
 
The logistic regression analysis in Table 15 was performed without the 4 cases in 
which there was diagnostic uncertainty.  Although there were minor variations in the 
odds ratios obtained, the same variables remained statistically significant, 















Gender (female) 0.878 0.421 – 1.833 0.729 
Age (per year) 1.092 1.027 – 1.162 0.005 
In social class IIIM (skilled manual occupations), IV 
(partly-skilled occupations) or V (unskilled 
occupations) at wave 1 
1.854 0.870 – 3.951 0.110 
More functional incapacity (score 11-18) according 
to modified Townsend disability score  
1.888 0.676 – 5.267 0.225 
Total CIRS-G score (per point) 1.091 0.993 – 1.199 0.070 
Clinical Frailty Score (per point) 1.194 0.853 – 1.672 0.301 
≤10 years in full time education 1.401 0.601 – 3.265 0.434 
Cognition at wave 2 interview measured using 
total CAMCOG (per point) 
0.955 0.914 – 0.997 0.035 
Table 16: Results of logistic regression analysis exploring baseline characteristics 
which independently predict delirium excluding the 4 cases in which the diagnosis 
was less certain and required a third expert assessor.  




4.2 Delirium specifics 
4.2.1 History of delirium 
8 of the 205 participants recruited to the DECIDE study in hospital had a history of 
delirium prior to the study period documented in their medical records.  62 of the 205 
had a history of delirium prior to the study period reported by them or their informant 
(30%).  A history of delirium in the medical records or from the patient or their 










Previous episode of delirium 
documented in medical records (%) 
7.32% 1.63% Yes 
(p=0.039) 
Previous episode of delirium reported 
by participant or informant (%) 
47.56% 18.70% Yes 
(p<0.000) 
 
Table 17: Comparison of the rates of delirium in those with and without a previous 
episode of delirium documented in their medical records or reported by the 
participant or their informant using Chi-squared test. 
 
4.2.2 Duration of delirium 
Mean total number of days with delirium during the study period was available for 76 
of the 82 participants with delirium and was 5.88 days, with a standard deviation of 
9.16 days.  Minimum number of days with delirium was 1 day and maximum was 59 
days.   
 
  




4.2.3 Motor subtype of delirium 
The motor subtype of delirium was evaluated using item 9 of the MDAS.  When more 
than one subtype occurred, this was recorded as mixed delirium.  Of the 82 people 
with delirium, 34 did not have a motor subtype defined according to MDAS item 9.  Of 
the participants with delirium who had a subtype defined, 14 had hyperactive 
delirium, 15 had hypoactive delirium and 19 had mixed delirium (Figure 18). 
 
  
Figure 18: Pie chart demonstrating the motor subtype of delirium, as per item 9 on 













4.2.4 Severity of delirium 
Delirium severity was measured using the Memorial Delirium Assessment Scale.  It 
was possible to calculate a peak delirium severity for 200 of the 205 participants.  5 
of the 205 participants remained untestable throughout their hospital admissions due 
to delirium and therefore did not have a recordable peak MDAS score.  3 of these 
people had delirium superimposed on advanced dementia.     
 
Mean peak delirium severity was 5.37 (SD 4.42) with minimum total score of 0 and 
maximum total score of 23.  When comparing those with and without delirium, using 
a Mann-Witney test due to the variable not being normally distributed, those who 
developed delirium during the study period had significantly higher peak MDAS 
scores (Table 18). 
 





Peak total MDAS score during study 







Table 18: Comparison of peak total MDAS scores in participants with and without 
delirium during the study period 
  




4.2.5 Number of episodes of delirium 
123 of the 205 participants recruited to DECIDE over the study period experienced 
no episodes of delirium.  58 participants had one episode of delirium, 17 had 2 
episodes and 7 participants had 3 or more episodes of delirium (Figure 19).     
 
 
Figure 19: Bar graph showing the number of episodes of delirium captured during the 


























Number of episodes of delirium during the study period




4.3 Perceptual disturbances 
4.3.1 Prevalence of perceptual disturbances 
65 of the 205 participants (31.7%) recruited in hospital answered “yes” when asked 
the following question when they were assessed as an inpatient: 
 
“Sometimes people in hospital can see and hear things that perhaps are not really 
there.  Have you had anything like that?” 
 
Most people reporting perceptual disturbances reported hallucinations (61%) (Figure 
20), and the majority of these were visual hallucinations (95%).  17% reported 
delusions and the remaining 22% reported both hallucinations and delusions. 
 
 
Figure 20: Pie chart to show the type of perceptual disturbances reported by DECIDE 
participants in hospital 
 
4.3.2 Association with delirium 
45 of the 65 people who reported perceptual disturbances (69.2%) fulfilled DSM-5 
criteria for delirium at the time and 30 reported feeling distressed at the time (46.2%).   
 
20 people who reported perceptual disturbances did not fulfil criteria for DSM 5 
delirium at the time that they reported the perceptual disturbances.  When exploring 
this, 7 reported experiences that had happened at night, 2 reported experiences at 








Parkinson’s Disease Dementia and experienced hallucinations as part of these 
conditions.  1 participant was withdrawing from alcohol.  2 participants had dementia 
and had delirium before and after reporting perceptual disturbances.  This may 
suggest that they needed to recover sufficiently from their delirium in order to 
communicate their experience.  3 people had “misperceptions or illusions related to 
sleep” according to the Memorial Delirium Assessment Scale which included 1 vivid 
dream which possibly continued on waking, 1 daydream and 1 misrepresentation 
when they saw their mother’s face in a cloud.  This left 3 people who reported true 
visual hallucinations but did not have delirium at the time.  
 
4.3.3 What did participants report? 
Participants reported a variety of visual hallucinations including animals such as 
horses, dogs, mice, birds and people dressed up as animals.  Participants reported 
seeing people, on the ward or at the window, including children, clowns and the 
Virgin Mary.  Some participants reported seeing vehicles including tractors and a 
yellow bus whilst another participant could see prices on the ceiling tiles.  Several 
participants reported seeing dirt everywhere on the ward.   
 
In terms of the delusions, it was common for participants to report having been 
somewhere else including a space station, a football match, into town, to the doctor’s 
surgery, on a boat and to prison.  Several people mentioned that this was not a real 
hospital and that all the staff were “in on it”.  Several people thought that there had 
been fighting on the ward.  One participant thought that the hospital had been sold to 
a brewery.   
 
  




4.3.4 Demographics of participants with perceptual disturbances 
Participants who experienced perceptual disturbances were significantly older, more 
likely to have a diagnosis of dementia recorded in their hospital records and had 






(n = 65) 
Did not report 
perceptual 
disturbances 




Age (mean) 83.72 81.26 P=0.0114 
(independent t 
test) 
Gender (% female) 31 (47.69%) 78 (55.71%) P=0.284 
(chi-squared test) 
Dementia reported 11 (16.92%) 10 (7.14%) P=0.032 
(chi-squared 
test) 




23 (35.38%) 39 (27.86%) P=0.275 
(chi-squared test) 
Co-morbidities  
(mean total CIRS-G 
score)  
10.14 7.82 P=0.0003 
(independent t 
test) 
Total Rockwood Clinical 
Frailty Score on first 
admission 
4.83 3.99 P=0.0001 
(independent t 
test) 
Table 19: Comparison of baseline characteristics in those who reported and did not 












Chapter 5: Results – Outcomes at 1 year 
 
5.1 Interviews at 1 year 
5.1.1 Number of interviews completed 
135 of the 205 participants recruited to DECIDE in hospital completed follow up 
interviews one year after their hospital admission (65.9%) (Figure 21).  38 of the 205 
participants died prior to the follow up interview (18.5%).  Of the remaining 32 
participants not seen at one year, 1 had moved out of the region and 31 refused 



















Figure 21: Flowchart showing the proportion of DECIDE participants who completed 
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5.1.2 Time between interviews 
For the 135 participants who completed a follow up interview, mean number of years 
between participants’ wave 2 interview, as part of CFAS II-Newcastle, and their follow 
up interview for DECIDE, was 4.51 years (SD 0.83 years) with minimum 3 years and 
maximum 6 years.  This was equal to a mean number of days between interviews of 
1665 days (SD 264.21) with minimum 1221 days and maximum 2271 days. 
 
5.2 Change in residence at 1 year 
115 participants remained at the same level of accommodation between first 
admission to hospital and follow up interview.  20 of 135 participants had a change in 
their level of residence between first hospital admission during the study period and 
the follow up interview at one year (Figure 22 and Figure 23).  At recruitment to 
DECIDE, 4 participants (2.96%) who were followed up at 1 year lived in residential or 

























































Figure 23: Graph representing the proportion of DECIDE participants followed up at 1 year at each level of residence at wave 2 
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5.3 Cognitive assessments at follow up 
5.3.1 CAMCOG 
117 of the 135 DECIDE participants who were interviewed one year after their last 
hospital discharge of the study period completed a CAMCOG.  Of the 18 participants 
who were not able to complete a full CAMCOG: 
• 13 were not able to complete a full CAMCOG due to cognitive 
impairment and received an AGECAT diagnosis of dementia.  10 were 
able to complete a MMSE.   
• 1 received an AGECAT diagnosis of depression and had a MMSE 
score of 24. 
• 4 were unable to complete a full CAMCOG due to hearing or visual 
impairment in 3 cases and due to refusal in one case.  All 4 were able 
to complete a MMSE and achieved scores of 19, 20, 20 and 22.  None 
received an AGECAT diagnosis of dementia, depression or anxiety.   
 
5.3.2 MMSE 
132 of the 135 DECIDE participants who were interviewed one year after last hospital 
discharge completed a MMSE.  3 participants were unable to complete a MMSE due 
to advanced dementia and all three received a study diagnosis of dementia, 1 of 
which was a new diagnosis since wave 2 interview. 
 
5.3.3 AGECAT diagnosis of dementia 
23 of the 135 participants interviewed one year after their last hospital discharge 
received an AGECAT diagnosis of dementia.  Only 5 of these participants had an 
AGECAT diagnosis of dementia at wave 2 meaning that there were 18 new cases of 
dementia between wave 2 and follow up as part of the DECIDE study.   
 
At wave 2, 9 of the 205 DECIDE participants had a diagnosis of dementia.  4 of these 
died before their follow up interview but the remaining 5 were seen again. 
 
  




5.4 Poor outcomes at follow up 
A poor outcome was defined as death, new institutionalisation or a new AGECAT 
diagnosis of dementia since wave 2 interview.  Excluding those participants who 
refused to be followed up at one year or had moved (32 participants of 205), a poor 
outcome occurred in 63 of the remaining 173 DECIDE participants (36.4%) (Figure 




Figure 24: Number of DECIDE participants followed up at 1 year experiencing a poor 
outcome defined as death, new institutionalisation or new dementia since wave 2 
interview 


































5.5 Impact of delirium on outcomes 
Outcomes including cognition, new institutionalisation and mortality, in participants 
who did and did not have delirium during the study period, were compared (Table 
20).  All of the outcomes in the table showed a statistically significant difference 
between those with and without delirium when tested individually. 
 
Multiple regression analysis was used to determine whether delirium remained a 
statistically significant predictor of the outcomes shown in Table 20 when controlling 
for the potentially confounding effects of age, gender, illness severity, comorbidity, 
frailty, baseline cognition, years of education and the time between the two interviews 
taking place.   
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interview (mean, SD) 
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(n=33) 
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MMSE score at follow up interview 
(mean, SD) 
21.82 +/- 5.84 
(n=45) 






Difference in MMSE score 
between wave II interview and 
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Table 20: Comparison of outcomes between those with and without delirium during 
the study period 




5.5.1 CAMCOG score 
The only variable that independently predicted cognition at one year, when using 
CAMCOG score at the follow up interview as the primary outcome measure, was 
CAMCOG score at wave 2 (p<0.000).  The potentially confounding effects of years of 
education, illness severity, comorbidity, time between interviews, frailty, age and 
gender were considered by including these variables in the regression analysis 
(Table 21).   
 
Variable Coefficient 95% confidence interval P value 
Delirium during 2016 (yes) -4.078 -8.514 - 0.358 0.071 
≤10 years in full time education 
(yes) 
-1.034 -4.861 - 2.794 0.593 
Peak total adjusted APACHE score 
(points) 
-0.195 -1.006 - 0.616 0.634 
Total CIRS-G score (per point) -0.045 -0.564 - 0.473 0.862 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
-0.004 -0.010 - 0.003 0.281 
Clinical Frailty Score (per point) -0.693 -2.376 – 0.990 0.416 
Age (years) -0.302 -0.622 - 0.018 0.064 
Gender (female) -0.650 -4.213 - 2.914 0.718 
Cognition at wave 2 interview 
measured using total CAMCOG 
(per point) 
0.881 0.591 - 1.171 0.000 
Table 21: Results of regression analysis exploring variables which independently 
predict cognition, measured using CAMCOG score, at one year after hospital 
admission 
 
Sensitivity analysis was carried out by excluding the 4 cases in which there was 
disagreement in the decision resulting in a third expert panel member creating a 
majority decision.  This did not alter the results of the analysis and CAMCOG score at 
wave 2 interview remained as the only significant predictor of CAMCOG score at 
follow up interview when controlling for potentially confounding variables.  
 





In the regression analysis using MMSE as the primary outcome measure, delirium, 
frailty score and MMSE score at wave 2 were the only variables remaining 
statistically significant predictors of MMSE score at follow up interview when 
controlling for the potentially confounding impact of years of education, illness 
severity, comorbidity, time between interviews and gender (Table 22).  Having 
delirium during the study period was associated with a reduction in MMSE score of 
1.828 points.   
 
Variable Coefficient 95% confidence interval P value 
Delirium during 2016 (yes) -1.828 -3.472 - -0.184 0.030 
≤10 years in full time education 
(yes) 
-0.183 -1.640 - 1.275 0.804 
Peak total adjusted APACHE score 
(points) 
-0.190 -0.476 - 0.095 0.189 
Total CIRS-G score (per point) -0.075 -0.259 - 0.109 0.419 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
-0.001 -0.004 - 0.001 0.362 
Clinical Frailty Score (per point) -0.638 -1.247 - -0.028 0.040 
Age (years) -0.074 -0.199 - 0.051 0.242 
Gender (female) 0.290 -1.053 - 1.634 0.669 
Cognition at wave 2 interview 
measured using total MMSE (per 
point) 
0.658 0.395 - 0.921 0.000 
Table 22: Results of regression analysis exploring variables which independently 
predict cognition, measured using MMSE score, at one year after hospital admission 
 
Sensitivity analysis, carried out without the 4 contentious cases, resulted in clinical 
frailty score no longer being a significant predictor of outcome.  Delirium (coef. -2.027 
[CI: -3.651 - -0.403], p=0.015) and baseline cognition (coef. 0.674 [CI: 0.413 – 0.935], 
p<0.000) remained the only independent predictors of outcome. 
 




5.5.3 New dementia diagnosis 
In the logistic regression analysis using new AGECAT diagnosis of dementia as the 
primary outcome measure, delirium was the only variable remaining a statistically 
significant predictor (OR 8.759 [CI: 1.854 – 41.368], p=0.006) when controlling for the 
potentially confounding impact of years of education, illness severity, comorbidity, 
time between interviews, frailty, age, gender and baseline cognition (measured using 
MMSE score) (Table 23).  
 
Variable Odds ratio 95% confidence interval P value 
Delirium during 2016 (yes) 8.759 1.854 – 41.368 0.006 
≤10 years in full time education 
(yes) 
0.868 0.221 – 3.405 
0.839 
Peak total adjusted APACHE score 
(points) 
0.844 0.654 – 1.090 
0.195 
Total CIRS-G score (per point) 1.066 0.907 – 1.254 0.437 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
1.001 0.998 – 1.003 
0.599 
Clinical Frailty Score (per point) 1.393 0.783 – 2.479 0.259 
Age (years) 1.022 0.920 – 1.135 0.685 
Gender (female) 1.163 0.338 – 3.999 0.810 
Cognition at wave 2 interview 
measured using total MMSE (per 
point) 
0.961 0.810 – 1.140 
0.648 
Table 23: Results of regression analysis exploring variables which independently 
predict new dementia diagnosis, according to the AGECAT, at one year after hospital 
admission.   
 
The sensitivity analyses did not alter the results. 
 
The analysis in Table 23 shows that an episode of delirium during the study period 
was associated with more than an 8 times increased risk of a new diagnosis of 
dementia at follow up, independent of illness severity and baseline cognition.  The 
confidence interval is quite wide, demonstrating some uncertainty regarding the 
magnitude of the precise odds ratio, probably due to the relatively small sample size.   





On further examination of this variable, Table 24 can be produced.  This table shows 
that there were very few people who had a new diagnosis of dementia at follow up 
interview who had not had delirium during the study period (3 people).  The small 
number of people in this category probably contributes to the large confidence 
interval surrounding the odds ratio. 
 
 Delirium during study 
period 
No delirium during study period 
New AGECAT diagnosis 
of dementia at follow up 
interview  
15 3 
No new AGECAT 
diagnosis of dementia at 
follow up interview 
33 84 
Table 24: Table demonstrating the number of participants with an AGECAT diagnosis 
of dementia who had delirium during the study period. 
 
The analysis in Table 23 included participants who had a diagnosis of dementia at 
wave 2 within the ‘no new dementia’ outcome group.  However, if these 5 participants 
are excluded from the analysis, the odds ratio of new dementia associated with 
delirium is increased to 9.52 (Table 25). 
9 of the 21 participants who had a documented diagnosis of dementia in their medical 
records on admission to hospital completed a follow-up interview.  Only 3 of these 
participants had a diagnosis of dementia at wave 2.  Therefore, 6 of the participants 
had potentially been diagnosed with dementia between their wave 2 interview and their 
admission to hospital and recruitment to the DECIDE study.  The analysis in Table 25 
was repeated, additionally excluding the 6 participants who had a documented 
diagnosis of dementia on admission to hospital (Table 26).  Delirium remained the only 
independent predictor of new dementia.      




Variable Odds ratio 95% confidence interval P value 
Delirium during 2016 (yes) 9.516 1.943 – 46.591 0.005 
≤10 years in full time education 
(yes) 0.897 0.218 – 3.697 0.881 
Peak total adjusted APACHE score 
(points) 0.925 0.699 – 1.223 0.582 
Total CIRS-G score (per point) 1.039 0.875 – 1.234 0.661 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
1.001 0.998 – 1.003 0.662 
Clinical Frailty Score (per point) 1.668 0.886 – 3.142 0.113 
Age (years) 0.971 0.857 – 1.101 0.649 
Gender (female) 1.180 0.317 – 4.396 0.805 
Cognition at wave 2 interview 
measured using total MMSE (per 
point) 
0.850 0.694 – 1.040 0.114 
Table 25: Results of regression analysis exploring variables which independently 
predict new dementia diagnosis, according to the AGECAT, at one year after hospital 
admission, excluding the 5 participants who had a diagnosis of dementia at wave 2.  
  
Variable Odds ratio 95% confidence interval P value 
Delirium during 2016 (yes) 9.846 1.515 – 63.992 0.017 
≤10 years in full time education 
(yes) 0.591 0.128 – 2.735 0.501 
Peak total adjusted APACHE score 
(points) 0.918 0.668 – 1.263 0.601 
Total CIRS-G score (per point) 0.967 0.798 – 1.172 0.732 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
1.000 0.998 – 1.003 0.707 
Clinical Frailty Score (per point) 1.142 0.581 – 2.244 0.699 
Age (years) 0.998 0.870 – 1.144 0.974 
Gender (female) 0.987 0.235 – 4.154 0.986 
Cognition at wave 2 interview 
measured using total MMSE (per 
point) 
0.812 0.649 – 1.016 0.069 
Table 26: Results of regression analysis exploring variables which independently 
predict new dementia diagnosis, according to the AGECAT, at one year after hospital 
admission, excluding the 5 participants who had a diagnosis of dementia at wave 2 
and the 6 participants who had a diagnosis of dementia documented in their medical 
records on admission to hospital.    




5.5.4 New institutionalisation 
Delirium was not an independent predictor of new institutionalisation.  However, 
illness severity, measured using peak total APACHE II score, and Clinical Frailty 
Score were independent predictors of new institutionalisation (Table 27).   
 
Variable Odds ratio 95% confidence interval P value 
Delirium during 2016 (yes) 1.192 0.155 – 9.182 0.866 
≤10 years in full time education 
(yes) 
0.255 0.038 – 1.710 0.159 
Peak total adjusted APACHE 
score (points) 
1.421 1.045 – 1.933 0.025 
Total CIRS-G score (per point) 1.059 0.853 – 1.316 0.603 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
1.001 0.998 – 1.005 0.507 
Clinical Frailty Score (per point) 2.729 1.035 – 7.197 0.042 
Age (years) 1.061 0.906 – 1.244 0.462 
Gender (female) 0.846 0.137 – 5.210 0.857 
Cognition at wave 2 interview 
measured using total MMSE (per 
point) 
0.886 0.709 – 1.106 0.285 
Table 27: Results of regression analysis exploring variables which independently 
predict new institutionalisation at one year after hospital admission 
 
The sensitivity analyses did not alter the results. 
 
As with the analysis of cognitive outcomes at one year, the above analysis is subject 
to survival bias. 
  




5.5.5 Death at 1 year 
Delirium was not an independent predictor of death by 1 year follow up but illness 
severity, measured using peak total APACHE II score, and Clinical Frailty Score did 
independently predict death by 1 year follow up (Table 28).    
 
Variable Odds ratio 95% confidence interval P value 
Delirium during 2016 (yes) 1.363 0.499 – 3.723 0.546 
≤10 years in full time education 
(yes) 
0.573 0.224 – 1.469 0.246 
Peak total adjusted APACHE 
score (points) 
1.234 1.058 – 1.439 0.007 
Total CIRS-G score (per point) 0.993 0.890 – 1.106 0.893 
Clinical Frailty Score (per point) 1.790 1.192 – 2.690 0.005 
Age (years) 0.957 0.886 – 1.033 0.256 
Gender (female) 0.462 0.196 – 1.089 0.078 
Cognition at wave 2 interview 
measured using total MMSE (per 
point) 
1.010 0.877 – 1.165 0.886 
Table 28: Results of regression analysis exploring variables which independently 
predict death before one year follow up 
 









5.5.6 Poor outcome 
Delirium, illness severity, measured using peak total APACHE II score, and Clinical 
Frailty Score all independently predicted poor outcome (death, new dementia or new 
institutionalisation) according to logistic regression analysis (Table 29). 
 
Variable Odds ratio 95% confidence interval P value 
Delirium during 2016 (yes) 3.536 1.412 – 8.856 0.007 
≤10 years in full time education 
(yes) 
0.451 0.178 – 1.140 0.092 
Peak total adjusted APACHE 
score (points) 
1.181 1.006 – 1.387 0.042 
Total CIRS-G score (per point) 1.042 0.932 – 1.166 0.466 
Clinical Frailty Score (per point) 1.766 1.213 – 2.571 0.003 
Age (years) 0.965 0.896 – 1.039 0.342 
Gender (female) 0.629 0.275 – 1.439 0.273 
Cognition at wave 2 interview 
measured using total MMSE (per 
point) 
0.885 0.764 – 1.024 0.102 
Table 29: Results of regression analysis exploring variables which independently 
predict poor outcome 
 
On sensitivity analysis, and removal of the four contentious cases, only delirium (OR 
3.482 (1.370 - 8.850), p=0.009) and Clinical Frailty Score (OR 1.739 (1.190 - 2.542), 
p=0.004) remained statistically significant predictors of poor outcome.   
 
An episode of delirium during the study period was associated with a 3.5 times 










5.6 Impact of hospital admission on outcomes 
It was possible to explore the impact of hospital admission itself on outcomes by 
comparing the cognitive scores at follow up interview in the 135 DECIDE participants 
recruited in hospital and followed up at one year to the 100 control participants who 
had no hospital admissions during the study period.  As previously mentioned, the 
controls were matched to the DECIDE participants for age, gender and years of 
education.   
5.6.1 MMSE 
Mean MMSE score at follow up interview in the control group was 27.17 (SD 2.910) 
compared to 25.023 (SD 4.854) if the hospitalised group.  This difference was 
statistically significant (p = 0.0005) when using two-sample Wilcoxon rank-sum test 
as MMSE score was not normally distributed.  When controlling for baseline cognition 
and time between wave 2 and follow up interview using regression analysis, 
hospitalisation remained a significant predictor of MMSE score at follow up interview 
(Table 30). 




No hospital admission during 2016 1.182 0.252 – 2.113 0.013 
Cognition at wave 2 interview (MMSE 
score) 
0.915 0.739 – 1.091 <0.000 
Days between interviews -0.001 -0.003 – 0.001 0.426 
Table 30: Regression analysis exploring variables which independently predict 
MMSE score at follow up interview  
 
It is also possible to compare cognitive decline (measured using MMSE scores) in 
those admitted to hospital who had delirium, to those admitted to hospital who did not 
develop delirium, with those who had no admissions to hospital during the study 
period (Table 31). 
The groups are significantly different from one another (p<0.000).  However, when you 
remove the participants who had delirium during the study period and compare those 
who were hospitalised but did not have delirium (n=87) to those who were not 
hospitalised (n=100), there was no significant difference in their MMSE scores at follow 
up interview (p=0.2731).  When controlling for the confounding effects of baseline 




cognition and days between the baseline and follow up interviews, hospitalisation was 
not an independent predictor of MMSE score at follow up interview (Table 30). 
 Mean MMSE score 
at follow up 
interview 
Standard deviation Frequency 
Hospital admission 
and delirium  
21.822 5.844 45 
Hospital admission, 
no delirium  
26.678 3.208 87 
No hospital 
admission  
27.17 2.910 100 
Table 31: Comparison of MMSE score at follow up interview in those admitted to 
hospital who had delirium compared to those admitted to hospital who did not 
develop delirium and those who had no admissions to hospital during the study 
period using one way ANOVA 
 
Variable Coefficient 95% confidence interval P value 
Hospital admission during 2016 but 
NO delirium (n=87) 
-0.125 -0.861 – 0.611 0.738 
Cognition at wave 2 interview 
(MMSE score) 
0.833 0.669 – 0.997 <0.000 
Days between interviews -0.000 -0.002 – 0.001 0.808 
Table 32: Regression analysis exploring whether hospitalisation without delirium 
compared to no hospitalisation independently predicted MMSE score at follow up 
interview  
 
This implies that the hospitalisation itself is not impacting on cognitive outcomes but 
the delirium in addition to hospitalisation results in adverse cognitive outcomes.   
 
5.6.2 Number of hospital admissions 
Mean number of hospital admissions in those who did develop delirium during the 
study period was 2.037 compared to 1.813 for those who did not develop delirium.  
However, the number of hospital admissions did not differ significantly between 
participants who did and did not develop delirium (p=0.115).  Additionally, when 
included as a potential confounder, number of admissions did not alter the results of 
regression analysis exploring variables which independently predict outcomes.   
 
  




5.7 Informant history of delirium using I-AGeD 
At all of the follow up interviews, with the verbal consent of the participant, a 
nominated next of kin was asked to complete the Informant Assessment of Geriatric 
Delirium Scale (I-AGeD).  This was done in person, if the next of kin was with the 
participant, or over the telephone following the interview with the participant.   
 
An I-AGeD questionnaire was completed for 113 of the 135 DECIDE participants 
interviewed 1 year after their hospital admission and 47 of the 100 controls 
interviewed.  Figure 25 shows the scores obtained on completion of the 
questionnaire.   
 
   
Figure 25: Percentage of DECIDE participants and control participants interviewed at 
1 year scoring 0 to 10 on Informant Assessment of Geriatric Delirium Scale (I-AGED) 






























A cut-off of >4 was used for delirium in the original article (Rhodius-Meester et al., 
2013).  At this cut-off, none of the controls and 33 of the DECIDE participants had a 
history from their informant suggestive of delirium.   
 
Using the diagnosis of delirium obtained prospectively for the DECIDE study as a 
gold standard, it is possible to assess the diagnostic accuracy of the I-AGeD for 
ascertaining a retrospective diagnosis of delirium over the preceding year.  Using 
AUROC analysis, a cut off of >4 classifies the most cases correctly (78.76%) and 
gives a sensitivity of 60.47% and a specificity of 90.00% (Figure 26) and an area 
under the ROC curve of 0.8231. 
 
 
Figure 26: ROC curve for delirium diagnosis using I-AGED compared to DECIDE 
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Chapter 6: Predictors of poor outcomes 
 
Exploratory analysis was carried out to determine whether delirium duration, delirium 
severity, delirium motor subtype, presence of perceptual disturbances or number of 
episodes of delirium impacted on outcomes including CAMCOG score, MMSE score, 
new AGECAT diagnosis of dementia, new institutionalisation, death prior to follow up 
interview at 12 months and a combination of these.  The potentially confounding 
effects of age, gender, years of education, baseline cognition, illness severity, 
comorbidity, frailty and the time between the interviews were controlled for in the 
analysis.  All output from statistical analysis is summarised in this section where 
relevant. 
6.1 Delirium duration as a predictor of outcome 
Data on the total number of days of delirium during the study was available for 76 of 
the 82 participants with delirium.  48 of the participants with delirium were followed up 
at 1 year and 44 of these had complete data regarding total number of days of 
delirium. 
Delirium duration was divided into 3 categories for the purpose of the analysis due to 
the fact that the variable was skewed, with large numbers of participants having no 
days of delirium (Table 33).  The numbers of participants within each subgroup is 
small, particularly when examining cognitive outcomes, and so the analysis is 
exploratory and the conclusions that can be drawn are limited.   







(n = 199) 
Number of participants 
followed up at 1 year 
(% of total number of 
participants in 
subgroup) 
Number of participants 
completing a CAMCOG 
at 1 year (% of total 
number of participants in 
subgroup) 
0 123  87 (70.7%) 84 (68.3%) 
1-5 52  35 (67.3%) 25 (48.1%) 
>5 24  9 (37.5%) 5 (20.8%) 
Table 33: Total number of days with delirium during the study period for the 76 
participants who had delirium and had data regarding duration available.  123 
participants did not experience delirium during the study period and therefore have a 
delirium duration of 0 days. 




6.1.1 CAMCOG score 
Total number of days of delirium was not an independent predictor of CAMCOG 
score.  CAMCOG score at wave 2 interview was the only independent predictor of 
CAMCOG score at follow up (coef. 0.825 [CI: 0.552 – 1.099], p<0.000) (Table 34). 
Variable Coefficient 95% confidence interval P value 
Age (years) -0.243 -0.545 – 0.058 0.112 
Gender (female) 0.537 -2.866 – 3.939 0.755 
≤10 years in full time education 
(yes) 
-2.653 -6.315 – 1.009 0.154 
Cognition at wave 2 interview 
measured using total CAMCOG 
score (per point) 
0.825 0.552 – 1.099 0.000 
Peak total adjusted APACHE score 
(points) 
-0.040 -0.804 – 0.724 0.917 
Total CIRS-G score (per point) -0.028 -0.516 – 0.459 0.908 
Clinical Frailty Score (per point) -0.376 -1.972 – 1.220 0.641 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
-0.003 -0.009 – 0.004 0.412 






-4.300 -8.704 – 0.105 0.056 
>5 days -7.982 -17.363 – 1.398 0.094 
Table 34: Results of regression analysis exploring variables which independently 
predict cognition, measured using CAMCOG score, at one year after hospital 
admission.  




6.1.2 MMSE score 
Having delirium for more than 5 days was independently associated with a 5 point 
reduction in MMSE score at follow up interview (coef. -5.132 [CI: -8.139 - -2.125], 
p=0.001).  Having delirium for 1-5 days was also independently associated with a 
significant, although not as large, reduction in MMSE score at follow up interview 
(Table 35).   
Variable Coefficient 95% confidence interval P value 
Age (years) -0.044 -0.166 – 0.078 0.475 
Gender (female) 0.466 -0.856 – 1.788 0.486 
≤10 years in full time education 
(yes) 
-0.326 -1.762 – 1.109 0.653 
Cognition at wave 2 interview 
measured using total MMSE 
score (per point) 
0.667 0.406 – 0.928 0.000 
Peak total adjusted APACHE score 
(points) 
-0.179 -0.456 – 0.098 0.202 
Total CIRS-G score (per point) -0.027 -0.207 – 0.154 0.770 
Clinical Frailty Score (per point) -0.459 -1.065 – 0.146 0.136 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
-0.001 -0.003 – 0.002 0.452 
Total number 






-1.726 -3.405 - -0.048 0.044 
>5 days -5.132 -8.139 - -2.125 0.001 
Table 35: Results of regression analysis exploring variables which independently 
predict cognition, measured using MMSE score, at one year after hospital admission. 
  




6.1.3 New dementia diagnosis 
Delirium duration of 1-5 days independently predicted a new AGECAT diagnosis of 
dementia at follow up interview (Table 36).  The confidence interval is quite wide 
suggesting some uncertainty regarding the magnitude of the increased risk 
associated with this duration of delirium.  Having delirium for more than 5 days did 
not reach statistical significance, perhaps due to the small numbers involved. 
Variable Odds ratio 95% confidence interval P value 
Age (years) 1.030 0.924 – 1.147 0.597 
Gender (female) 1.045 0.296 – 3.694 0.946 
≤10 years in full time education 
(yes) 
0.816 0.196 – 3.399 0.780 
Cognition at wave 2 interview 
measured using total MMSE score 
(per point) 
0.937 0.787 – 1.115 0.461 
Peak total adjusted APACHE score 
(points) 
0.855 0.665 – 1.099 0.222 
Total CIRS-G score (per point) 1.070 0.901 – 1.270 0.440 
Clinical Frailty Score (per point) 1.359 0.752 – 2.453 0.309 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
1.001 0.998 – 1.003 0.624 
Total number 






9.321 1.964 – 44.231 0.005 
>5 days 8.368 0.824 – 84.946 0.072 
Table 36: Results of logistic regression analysis exploring variables which 








6.1.4 New institutionalisation 
Delirium duration was not an independent predictor of new institutionalisation at 
follow up interview (Table 37). 
Variable Odds ratio 95% confidence interval P value 
Age (years) 1.039    0.876 - 1.232 0.660 
Gender (female) 0.817 0.132 – 5.063 0.828 
≤10 years in full time education 
(yes) 
0.318 0.039 – 2.566 0.282 
Cognition at wave 2 interview 
measured using total MMSE score 
(per point) 
0.917 0.733 - 1.146 0.446 
Peak total adjusted APACHE 
score (points) 
1.393 1.028 - 1.887 0.033 
Total CIRS-G score (per point) 1.091 0.848 - 1.403 0.498 
Clinical Frailty Score (per point) 2.641 0.986 – 7.077 0.053 
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
1.001 0.997 - 1.005 0.762 






1.392 0.168 – 11.499 0.759 
>5 days 0.701 0.034 – 14.416 0.818 
Table 37: Results of logistic regression analysis exploring variables which 
independently predict new institutionalisation at one year after hospital admission. 
 
  




6.1.5 Death prior to follow up interview 
Delirium duration was not an independent predictor of death prior to follow up 
interview (Table 38). 
Variable Odds ratio 95% confidence interval P value 
Age (years) 0.967 0.895 - 1.044 0.390      
Gender (female) 0.431 0.177 - 1.049 0.064      
≤10 years in full time education 
(yes) 
0.515   0.195 - 1.359 0.180      
Cognition at wave 2 interview 
measured using total MMSE score 
(per point) 
0.973 0.838 - 1.128 0.714      
Peak total adjusted APACHE 
score (points) 
1.178   1.008 - 1.376 0.039      
Total CIRS-G score (per point) 0.971 0.864 - 1.092 0.627      
Clinical Frailty Score (per point) 1.737 1.146 - 2.631 0.009      






1.079 0.356 - 3.270 0.893      
>5 days 2.716   0.660 - 11.182 0.166      
Table 38: Results of logistic regression analysis exploring variables which 








6.1.6 Poor outcome 
Delirium duration of 1-5 days and >5 days independently predicted a poor outcome 
by follow up interview (death, new dementia or new institutionalisation) along with 
frailty (Table 39). 
Variable Odds ratio 95% confidence interval P value 
Age (years) 0.965 0.895 – 1.040 0.351 
Gender (female) 0.564 0.242 – 1.311 0.183 
≤10 years in full time education 
(yes) 
0.466 0.182 – 1.192 0.111 
Cognition at wave 2 interview 
measured using total MMSE score 
(per point) 
0.867 0.746 – 1.009 0.065 
Peak total adjusted APACHE score 
(points) 
1.149 0.974 – 1.354 0.099 
Total CIRS-G score (per point) 1.029 0.918 – 1.153 0.623 
Clinical Frailty Score (per point) 1.673 1.141 – 2.452 0.008 
Total number 






3.430 1.297 – 9.073 0.013 
>5 days 4.936 1.116 – 21.836 0.035 
Table 39:  Results of logistic regression analysis exploring variables which 
independently predict poor outcome, defined as death, new dementia or new 
institutionalisation, at one year after hospital admission. 
  




6.2 Delirium severity as a predictor of outcome 
Delirium severity was recorded as the peak MDAS score recorded during the study 
period.  This data was available for 200 of the 205 participants recruited in hospital 
as it was recorded for people with and without delirium.  Of these, 133 were followed 
up at 1 year. 
6.2.1 CAMCOG score 
When including peak MDAS score during the study period in regression analysis, 
CAMCOG score at wave 2 interview was the only variable to reach statistical 
significance (coef. 0.857 [CI: 0.562 – 1.152], p<0.000) as an independent predictor of 
CAMCOG score at follow up interview.  
6.2.2 MMSE score  
The analysis was run again with MMSE score at follow up interview as the outcome 
measure and MMSE score at wave 2 interview as the measure of baseline cognition.  
MMSE score at wave 2 interview, frailty and peak total MDAS score during the study 
period were all statistically significant independent predictors of MMSE score at 
follow up interview (Table 40).  This suggests that having more severe delirium 
independently predicts worse cognitive outcomes.  In fact, for each MDAS point 
gained, indicating more severe delirium, a decline in MMSE score of 0.387 points 
was expected, independent of other variables.   
  








Age (years) -0.063 -0.184 – 0.058 0.307 
Gender (female) -0.009 -1.313 – 1.295 0.989 
≤10 years of education (yes) 0.305 -1.108 - 1.718  0.670 
Cognition at wave 2 interview measured 
using total MMSE score (per point) 
0.605 0.346 – 0.863 0.000 
Peak total adjusted APACHE score (per point) -0.118 -0.400 – 0.163 0.408 
Comorbidity  
(total CIRS-G score) (per point) 
-0.028 -0.210 – 0.154 0.760 
Clinical Frailty Score (per point) -0.594 -1.185 - -0.002 0.049 
Days between wave 2 interview and follow up 
interview for DECIDE study (days) 
-0.002 -0.004 – 0.001 0.144 
Delirium severity according to peak MDAS 
score during the study period (per point) 
-0.387 -0.606 - -0.168 0.001 
Table 40: Regression analysis exploring independent predictors of MMSE score at 
follow up interview including severity of delirium   




6.2.3 New dementia diagnosis  
In logistic regression analysis with new dementia diagnosis at follow up interview as 
the binary outcome measure, peak total MDAS score was the only variable that 
reached statistical significance as an independent predictor of outcome (OR 1.260 
[CI: 1.052 – 1.510], p=0.012), again suggesting that more severe delirium is 
independently associated with worse outcomes (Table 41).  Each MDAS point gained 







Age (years) 0.986 0.879 – 1.105 0.805 
Gender (female) 2.168 0.559 – 8.407 0.263 
≤10 years of education (yes) 0.707 0.184 – 2.727 0.615 
Cognition at wave 2 interview measured using 
total MMSE score (per point) 
0.886 0.732 – 1.073 0.215 
Peak total adjusted APACHE score (per point) 0.875 0.685 – 1.117 0.282 
Comorbidity  
(total CIRS-G score) (per point) 
1.033 0.873 – 1.221 0.706 
Clinical Frailty Score (per point) 1.677 0.914 – 3.079 0.095 
Days between wave 2 interview and follow up 
interview for DECIDE study (days) 
1.002 0.999 – 1.004 0.185 
Delirium severity according to peak MDAS 
score during the study period (per point) 
1.260 1.052 – 1.510 0.012 
Table 41: Logistic regression analysis exploring independent predictors of new 
AGECAT dementia diagnosis at follow up interview  
6.2.4 New institutionalisation 
In logistic regression analysis with new institutionalisation at follow up interview as 
the binary outcome measure, none of the variables reached statistical significance as 
independent predictors. 




6.2.5 Death prior to follow up 
When exploring predictors of death prior to follow up interview, illness severity, 
measured using peak total APACHE score during the study period (OR 1.248 [CI: 
1.059 – 1.471], p=0.008), clinical frailty score (OR 1.733 [CI: 1.129 – 2.659], 
p=0.012) and age (OR 0.919 [CI: 0.845 – 1.000], p=0.050) were the variables that 
reached statistical significance as independent predictors of death prior to follow up 
interview. 
6.2.6 Poor outcome 
When exploring predictors of poor outcome as the binary outcome measure, defined 
as new dementia, new institutionalisation or death prior to follow up interview, illness 
severity, frailty score and delirium severity were all significant independent predictors 
of outcome (Table 42).  This means that each point gained on the MDAS is 







Age (years) 0.967 0.897 – 1.042 0.377 
Gender (female) 0.805 0.349 – 1.856 0.610 
≤10 years of education (yes) 0.479 0.186 – 1.232 0.127 
Cognition at wave 2 interview measured using 
total MMSE score (per point) 
0.912 0.786 – 1.058 0.224 
Peak total adjusted APACHE score (per point) 1.193 1.008 – 1.411 0.040 
Comorbidity  
(total CIRS-G score) (per point) 
1.042 0.931 – 1.165 0.477 
Clinical Frailty Score (per point) 1.552 1.062 – 2.268 0.023 
Delirium severity according to peak MDAS 
score during the study period (per point) 
1.207 1.055 – 1.380 0.006 
Table 42: Regression analysis exploring independent predictors of poor outcome at 
follow up interview including severity of delirium  
 




6.3 Delirium motor subtype as a predictor of poor outcome 
Delirium motor subtype was defined as none, hypoactive, hyperactive or mixed, as 
per item 9 of the MDAS, for all 82 of the participants who had delirium during the 
study period.   
When including motor subtype during the study period in regression analysis, frailty 
score on first admission to hospital was the only variable to reach statistical 
significance (coef. -7.823 [CI: -14.776 - -0.869], p=0.029) as an independent 
predictor of CAMCOG score at follow up interview.  Similarly, frailty score on first 
admission to hospital was the only variable to reach statistical significance (coef. -
2.272 [CI: -4.347 - -0.197], p=0.033) as an independent predictor of MMSE score at 
follow up interview. 
Delirium motor subtype did not predict new dementia, new institutionalisation or poor 
outcome at follow up, independent of the other variables.   
Hyperactive delirium was a statistically significant predictor of death by follow up 
interview along with peak total APACHE score.  However, the numbers are very 







Age (years) 1.021 0.918 – 1.135 0.707 
Gender (female) 0.636 0.179 – 2.257 0.484 
≤10 years of education (yes) 1.403 0.282 – 6.972 0.679 
Cognition at wave 2 interview measured using 
total MMSE score (per point) 
1.048 0.860 – 1.277 0.642 
Peak total adjusted APACHE score (per 
point) 
1.281 1.035 – 1.586 0.023 
Comorbidity  
(total CIRS-G score) (per point) 
1.010 0.861 – 1.186 0.898 
Clinical Frailty Score (per point) 1.211 0.595 – 2.467 0.597 
Motor subtype - hypoactive 1.634 0.230 – 11.596 0.624 
Motor subtype - hyperactive 21.204 2.925 – 153.691 0.003 
Motor subtype - mixed 4.782 0.721 – 31.701 0.105 
Table 43: Regression analysis exploring independent predictors of death prior to 
follow up interview including delirium motor subtype  




6.4 Presence of perceptual disturbances as a predictor of poor outcome 
The presence or absence of perceptual disturbances did not independently predict 
CAMCOG score, MMSE score, new dementia, new institutionalisation, death prior to 
follow up or poor outcome at follow up. 
6.5 Number of episodes of delirium during the study period as a predictor of 
poor outcome 
The number of episodes of delirium during the study period was divided into 3 
categories for the purpose of the analysis due to the fact that the variable was highly 
skewed.  123 participants had no episodes of delirium during the study period, 58 
participants had 1 episode and 24 participants had more than 1 episode.   
6.5.1 CAMCOG score 
Having 1 episode of delirium during the study period was independently associated 
with a decline in CAMCOG score at follow up (coef. -5.098 [CI: -9.743 - -0.453], 
p=0.032) whilst having more than one episode was not.  However, the numbers are 
very small, with considerable subgroup differences in the proportion of participants 
surviving to one year follow up and also being able to complete a full CAMCOG, 
which may account for the slightly unexpected result.  For example, 9 of the 24 
people who had more than 1 episode of delirium completed a follow up interview 
(37.5%), with only 5 able to complete a full CAMCOG, whilst 39 of the 58 people with 
1 episode of delirium were followed up (67.2%), with 28 completing a full CAMCOG.   
6.5.2 MMSE score 
As with the CAMCOG as the primary outcome measure, having just 1 episode of 
delirium was an independent predictor of MMSE score at follow up interview, whilst 
more than 1 episode was not (Table 44).  1 episode of delirium is associated with a 
1.9 point decline in MMSE score at follow up (coef. -1.873 [CI: -3.567 - -0.179], 
p=0.031).  The reason for the non-significant relationship between more than 1 
episode of delirium and MMSE score is probably due to the small number of 
participants in this subgroup.   
  








Age (years) -0.073 -0.199 – 0.053 0.254 
Gender (female) 0.289  -1.060 – 1.638 0.672 
≤10 years in full time education (yes) 0.198 -1.271 – 1.666 0.790 
Cognition at wave 2 interview measured 
using total MMSE score (per point) 
0.658 0.394 – 0.923 0.000 
Peak total adjusted APACHE score (points) -0.200 -0.498 – 0.098 0.186 
Total CIRS-G score (per point) -0.076 -0.260 – 0.109 0.420 
Clinical Frailty Score (per point) -0.642 -1.256 - -0.029 0.040 
Days between wave 2 interview and follow up 
interview for DECIDE study (days) 
-0.001 -0.004 – 0.001 0.385 
Total number of episodes of 
delirium during study period 
1 episode 
 
-1.873 -3.567 - -0.179 0.031 
>1 
episode 
-1.496 -4.732 – 1.741 0.362 
Table 44: Regression analysis exploring independent predictors of MMSE score at 
follow up interview including number of episodes of delirium during the study period   




6.5.3 New dementia diagnosis 
1 or more episodes of delirium during the study period independently predicted new 
AGECAT diagnosis of dementia at follow up interview (Table 45).  Once again, due 
to the exploratory nature of the analysis, the numbers are fairly small and the 
confidence intervals are large. 
Variable Odds ratio 95% confidence interval P value 
Age (years) 1.024 0.921 - 1.138 0.661     
Gender (female) 1.162 0.336 - 4.014 0.812      
≤10 years in full time education 
(yes) 
0.888 0.225 - 3.505 0.865      
Cognition at wave 2 interview 
measured using total MMSE score 
(per point) 
0.960 0.808 - 1.139 0.639      
Peak total adjusted APACHE score 
(points) 
0.821 0.621 - 1.086 0.167      
Total CIRS-G score (per point) 1.063 0.903 - 1.252 0.465      
Clinical Frailty Score (per point) 1.390   0.778 - 2.482 0.266      
Days between wave 2 interview 
and follow up interview for 
DECIDE study (days) 
1.001 0.998 - 1.003 0.546      
Total number 






8.585 1.792 - 41.132 0.007      
>1 episode 13.889 1.278 - 150.981 0.031      
Table 45: Regression analysis exploring independent predictors of new AGECAT 
diagnosis of dementia at follow up interview including number of episodes of delirium 
during the study period  
 
6.5.4 New institutionalisation 
Number of episodes of delirium did not independently predict new institutionalisation 
at follow up interview. 




6.5.5 Death prior to follow up interview 
Number of episodes of delirium did not independently predict death prior to follow up 
interview.  However, there was a significant difference between the proportion of 
people surviving to the one year follow up interview depending on the number of 
episodes of delirium experienced (p<0.000) (Table 46).   
Number of episodes of 
delirium during the study 
period 
Alive at follow up 
interview (n = 135) 
Died prior to follow up 
interview (n = 38) 
0 87 (86.14%) 14 (13.86%) 
1 39 (76.47%) 12 (23.53%) 
>1 9 (42.86%) 12 (57.14%) 
Table 46: Number of participants surviving to one year follow up interview based on 
the number of episodes of delirium experienced during the study year 
  




6.5.6 Poor outcome 
Clinical frailty score and number of episodes of delirium independently predicted poor 
outcome at follow up interview (Table 47).   
Variable Odds ratio 95% confidence interval P value 
Age (years) 0.965 0.895 - 1.039 0.343       
Gender (female) 0.618 0.269 - 1.421 0.257      
≤10 years in full time education 
(yes) 
0.450 0.178 - 1.138 0.092      
Cognition at wave 2 interview 
measured using total MMSE score 
(per point) 
0.886 0.765 - 1.025 0.103      
Peak total adjusted APACHE score 
(points) 
1.164 0.985 - 1.374 0.075      
Total CIRS-G score (per point) 1.041 0.931 - 1.165 0.482      
Clinical Frailty Score (per point) 1.738 1.192 - 2.535 0.004       
Total number 






3.176 1.230 - 8.199 0.017      
>1 episode 5.956   1.331 - 26.646 0.020      
Table 47: Logistic regression analysis exploring independent predictors of poor 










Chapter 7: Discussion 
 
7.1 Summary 
The main finding from the DECIDE study is that delirium is independently associated 
with a significantly increased risk of future cognitive decline and dementia.   
The DECIDE study has provided a unique opportunity to robustly evaluate the 
relationship between delirium and future cognitive decline and dementia, 
substantially adding to the current literature which has significant methodological 
limitations. 
This chapter will summarise the main findings from the DECIDE study in the context 
of existing literature.  It will discuss the strengths and weaknesses of the study and 
make suggestions based on the findings for future delirium research studies.   
  




7.2 What the DECIDE study adds to current literature 
7.2.1 Cognitive outcomes after delirium 
For the first time, delirium has been shown to be significantly associated with a new 
diagnosis of dementia, independent of baseline cognition and illness severity, in a 
population-based cohort of older people (odds ratio 8.76 [CI: 1.85 – 41.37]).  
This supports findings from a study based upon data from the original Cognitive 
Function and Ageing Study cohort (CFAS I) which ascertained delirium 
retrospectively using an algorithmic approach (Davis et al., 2014).  Despite the 
differing methodologies used to ascertain delirium, the increased risks of new 
dementia diagnosis at two years following study-defined delirium were remarkably 
similar (odds ratio 8.82 [CI: 2.76 – 28.2]).  The sample size of 2197 was considerably 
larger than in DECIDE, which may account for the narrower confidence intervals. 
The results from DECIDE were also very similar to a population based study of over 
85 year olds which did not prospectively define delirium or control for illness severity 
(odds ratio 8.7 [CI: 2.1–35]) (Davis et al., 2012).  The similarities seen in the results 
from the population based studies that exist regarding cognitive outcomes after 
delirium, despite the very different methods of delirium and dementia ascertainment, 
add weight to the argument that delirium is independently associated with cognitive 
decline and new dementia diagnosis.  This association remains even when 
controlling for the potentially confounding effect of illness severity, which was 
recorded prospectively in DECIDE, addressing a key limitation of previous studies.  
This strengthens the argument for the hypothesis that delirium itself is neurotoxic, 
and not simply a reflection of severe illness or other confounding factors.  This 
argument is further strengthened when examining the results in the context of the 
Bradford Hill criteria which are useful for establishing whether results from 
epidemiological studies provide sufficient evidence to suggest a causal relationship 
(Table 48) (Hill, 1965).  The fact that such similar results have been obtained from 
such different cohorts, the strength of the relationship and the fact that it has been 
shown in DECIDE that longer duration and multiple episodes are associated with 
worse outcomes, all support the hypothesis that delirium in itself is toxic to the brain. 
 
  




Bradford Hill Criteria Supporting evidence 
1. Strength Delirium has been shown to be associated with an increased risk 
of dementia with a large odds ratio of 8.8. 
2. Consistency Consistent findings have been observed from very different 
cohorts in different countries, using differing methodologies for 
delirium and dementia ascertainment (OR 8.8 from CFAS I 
(Davis et al., 2014); OR 8.7 from Vantaa (Davis et al., 2012)). 
3. Specificity Not demonstrated in DECIDE 




DECIDE has demonstrated that longer duration, greater severity 
and multiple episodes of delirium are associated with worse 
cognitive outcomes. 
6. Plausibility A mechanism for the relationship between delirium and dementia 
is limited by current knowledge and further research is needed in 
this field. 
7. Coherence As above, there is a lack of knowledge of the underlying 
pathophysiology. 
8. Experiment Dementia prevention studies which focus on delirium 
intervention will provide the focus for future research. 
9. Analogy It is possible that the relationship between delirium and dementia 
is analogous to the relationship seen in rheumatoid arthritis 
whereby an acute flare contributes to the accumulation of chronic 
joint damage.  
Table 48: Interpreting the results from the DECIDE study in the context of the Bradford 
Hill Criteria demonstrates the strength of the argument that delirium is toxic to the brain 
and contributes to dementia. 
For the first time, the DECIDE study has also quantified the size of the cognitive 
decline that might be expected following an episode of delirium using a well-
recognised and widely used cognitive testing tool.  Having delirium during the study 
period was associated with a reduction in MMSE score of nearly 2 points between 
baseline and follow up interviews.  For comparison, the mean difference in MMSE 
score at 6 months in patients with Alzheimer’s disease treated with 10mg donepezil 




(the optimal treatment for dementia currently) compared to those treated with 
placebo was 1.05 points (Birks and Harvey, 2018).   
The prospective assessments facilitated exploratory analysis of delirium 
characteristics as predictors of poor outcome, which has not been possible 
previously in a population-based cohort due to the retrospective ascertainment of 
delirium.  Previous work has demonstrated that increased duration and severity of 
delirium were associated with worse outcomes in terms of mortality and 
institutionalisation (Jackson et al., 2016b).  The DECIDE study has additionally 
shown that these factors predict worse cognitive outcomes with more than 5 days of 
delirium shown to be associated with a 5 point reduction in MMSE score at follow up 
(coef. -5.132 [CI: -8.139 - -2.125]).  This is in line with a previous study of intensive 
care unit survivors, which found that having delirium for more than 5 days was 
associated with considerably worse cognitive outcomes measured using a battery of 
cognitive tests (Girard et al., 2010).   
The DECIDE study found that having more than 1 episode of delirium during the year 
long study period was associated with a nearly 14 times increased risk of new 
dementia (odds ratio 13.889 [CI: 1.278 - 150.981]) and a nearly 6 times increased 
risk of poor outcome at follow up (odds ratio 5.956 [CI: 1.331 - 26.646]).  Although a 
degree of caution is necessary with respect to the precise size of the effect, due to 
the small numbers involved, these results are novel as no previous studies have 
been able to explore the effect of multiple episodes of delirium as they have either 
ascertained delirium retrospectively or have only followed participants during one 
hospital admission.     
7.2.2 Delirium incidence 
The hospital associated incidence of delirium during the one year study period in the 
DECIDE participants was 40%.  This is comparable to previous studies, which found 
occurrence rates per admission between 11 and 64% depending on precise setting 
(Siddiqi et al., 2006, Inouye et al., 2014, Eeles et al., 2010).  The longitudinal 
monitoring for and detailed recording of delirium, including multiple hospital 
admissions, is entirely novel with no previous, comparable data.   
The estimated community incidence of delirium was based upon the I-AGeD score in 
the 100 control participants who had no hospital admissions during the study period.  
None of the 47 participants with a completed I-AGeD scored above the previously 




used cut-off of 4, suggesting that none of the control participants had delirium during 
the study year.  This very low incidence is consistent with the community prevalence 
of delirium previously estimated to be around 1% (Inouye et al., 2014).  However, the 
figures obtained from control participants in DECIDE are limited by the use of a 
retrospective tool and the low completion rates caused mainly by participants not 
giving permission to speak to a next of kin.   
7.2.3 Risk factors for delirium 
Age and baseline cognition were found to be significant independent predictors of the 
development of delirium, which is in line with previous work on the predisposing 
factors for delirium (Inouye et al., 2014).   
7.2.4 Dementia prevalence 
The overall prevalence of dementia at follow up in the DECIDE hospital participants 
was 17% (23/135).  This is considerably higher than the expected prevalence of 
dementia in the general population over 65 years (6.5%), based upon data from 
CFAS (Matthews et al., 2013).  The DECIDE participants had all been hospital 
inpatients in the year preceding follow up cognitive testing which may highlight the 
importance of hospital admission as a marker of risk of adverse outcome, including 
cognitive outcomes, in older people.  However, the relationship is complex.  
Cognitive impairment has been shown to be a risk factor for hospital readmission 
(Craven and Conroy, 2015).  In line with this, the DECIDE participants had lower 
cognitive test scores at baseline than the controls recruited who had no hospital 
admissions in the preceding year (Table 13).  Additionally, when comparing those 
who were hospitalised but never experienced delirium to those who were not 
hospitalised during the study period, hospitalisation was not found to be an 
independent predictor of MMSE score at follow up interview.  This implies that the 
hospitalisation itself is not impacting on cognitive outcomes but the delirium in 
addition to hospitalisation results in adverse outcomes.  This is supported by the 
findings from DECIDE that 31% (15/48) of participants with delirium and 3% (3/87) of 
those without delirium had a new diagnosis of dementia at follow up.  It has not 
previously been possible to explore this and tease apart the relationship between 
hospital admission, delirium and cognitive outcomes. 
7.2.5 Relationship between frailty and delirium 
In line with previous work (Persico et al., 2018), Clinical Frailty Score (Rockwood et 
al., 2005) was shown to differ significantly between those who did and did not 




develop delirium in hospital, with higher scores, indicating more frailty, in those who 
developed delirium.  However, in multivariate analysis, only age and baseline 
cognition were independently associated with delirium.  Many of the studies 
examining the link between delirium and frailty did not adequately control for relevant 
confounders (Persico et al., 2018), which may explain why our multivariate results 
differ from published studies. 
It has previously been shown that delirium and frailty independently predict mortality 
(Dani et al., 2018).  However, multivariate analysis in DECIDE showed that only 
frailty and peak illness severity independently predicted mortality.  This may reflect 
the differing methodology used with DECIDE capturing incident delirium over a year 
as opposed to prevalent delirium within the first 72 hours of hospital admission (Dani 
et al., 2018).  Frailty was also recorded differently with the Frailty Index being used 
by Dani et al, including acute physiological markers such as laboratory and 
examination findings, as opposed to the Clinical Frailty Score in DECIDE, which 
provides a brief, general overview of functioning prior to admission, determined by 
the rater following discussion with the participant or their next of kin.   
Although delirium did not independently predict mortality in DECIDE, delirium, frailty 
and baseline cognition independently predicted MMSE score at follow up and 
delirium, frailty and illness severity all independently predicted poor outcome as a 
whole.  Despite the fact that there is clearly overlap in what is captured when 
measuring cognition and frailty, with many frailty scores including a rating of 
cognition, they were both shown to independently predict cognitive decline.     
It is well recognised that the degree of Alzheimer’s neuropathology does not correlate 
well with clinical features of dementia (Wallace et al., 2019).  For example, some 
people with high levels of classical Alzheimer’s neuropathology found on post 
mortem, such as amyloid plaques and neurofibrillary tangles, do not have classical 
symptoms of dementia clinically, whilst other people may have very little in the way of 
classical neuropathology, but have very severe Alzheimer’s disease clinically.  It has 
been proposed that frailty may account for some of this heterogeneity and previous 
work has shown that frailty and classical Alzheimer’s disease neuropathology were 
independently associated with Alzheimer’s dementia (Wallace et al., 2019).  They 
found that individuals with a higher frailty score, indicating more severe frailty, had a 
weaker association between classical Alzheimer’s pathology and clinical dementia 
symptoms (Wallace et al., 2019).  As such, more frail individuals were less able to 




tolerate Alzheimer’s neuropathology so even small levels resulted in clinical 
dementia.    
A similar disassociation between classical neuropathology and dementia symptoms 
has also been shown with delirium (Davis et al., 2012).  This study showed that there 
was no significant association between dementia and the classical neuropathological 
markers in patients who had a history of delirium.  A further study, which included 
participants from the original Cognitive Function and Ageing Study, again showed 
that the cognitive decline expected with classical neuropathology of dementia was 
accelerated in the context of co-existing delirium (Davis et al., 2017).  This suggests 
that delirium may be associated with an alternative neurodegenerative pathology that 
is, in these studies, unmeasured and currently unknown.  This also supports the 
hypothesis that delirium itself is neurotoxic. 
The independent contribution of frailty, delirium and baseline cognition to cognitive 
decline shown in DECIDE demonstrates the complex relationship between physical 
and cognitive function and support previous findings from studies including 
neuropathology.  Clinically, the results demonstrate the prognostic role that frailty 
may have in older people with delirium.  The results also emphasise the importance 
of measuring and recording both physical and cognitive function in research studies 
and not examining these factors in isolation. 
A specific limitation in DECIDE was that baseline cognition and frailty were not 
measured simultaneously, with cognition measured when participants were last seen 
as part of CFAS II and frailty being recorded on recruitment to DECIDE, with 3 and 6 
years between these time points.   It is difficult to estimate the impact of this but time 
between interviews was included as a relevant confounder in multivariate analysis to 
try to account for this variability. 
7.2.6 Perceptual disturbances in delirium 
There is very little published literature describing and recording the perceptual 
disturbances experienced by patients with delirium and the relationship between 
these symptoms and outcomes, as well as patient experience, is poorly understood.   
The DECIDE study was in a unique position to document the reported perceptual 
disturbances in a population of older people in hospital with and without delirium.  
Perceptual disturbances were commonly reported by participants (31.7%) and 
frequently coincided with delirium (69.2%).  Participants who experienced perceptual 




disturbances were significantly older, more likely to have a diagnosis of dementia and 
had more co-morbidities.  
Previous studies have not recorded the prevalence of perceptual disturbances in a 
general hospital population but have focused on specific patients, mainly people with 
delirium.  In a study of 100 palliative care patients with delirium, 49 had evidence of 
psychosis which was defined as the presence of perceptual disturbances, delusions 
or thought disturbance as recorded using the Delirium Rating Scale-Revised-98 
(Meagher et al., 2007).  A study of 100 patients with delirium from a cancer hospital 
in New York found that the prevalence of perceptual disturbances and delusions was 
higher in patients with hyperactive (70.2% and 78.7% respectively) than hypoactive 
delirium (50.9% and 43.4% respectively), as recording using the Memorial Delirium 
Assessment Scale (MDAS) (Boettger and Breitbart, 2011).  However, there is 
methodological uncertainty surrounding this study as none of the participants were 
unable to complete the full MDAS.  In DECIDE, it was not always possible to 
complete the full MDAS, particularly those sections which required patients to 
demonstrate perceptual disturbances and delusions, due to delirium with severe 
inattention or deranged level of arousal or due to advanced cognitive impairment 
rendering patients mute.  It is unclear whether these patients were simply excluded 
by Boettger et al, which would probably result in an underestimation of the true 
prevalence. 
It was perhaps surprising to discover how many older people in hospital have these 
experiences, even when not associated with delirium.  When focusing on the 
participants who did not have delirium at the time, nearly half of participants 
described these experiences happening at night.  It is possible that these participants 
had a brief period of delirium, which was not captured by the daily assessments.  
This reflects the fluctuating nature of delirium and the challenges of prospectively 
capturing it.  This may also be the case for the 2 participants who had these 
experiences at home immediately prior to admission.  The 2 participants with 
dementia in whom the experiences were reported on a day with no delirium 
surrounded by days of delirium before and after may suggest that they needed to 
recover sufficiently from their delirium in order to communicate their experiences.    3 
people had “misperceptions or illusions related to sleep” according to the Memorial 
Delirium Assessment Scale.  The studies mentioned above would not have included 
these people in their analyses as they only included people with perceptual 




disturbances or delusions rated 2 or above on the MDAS.  This left 3 people who 
reported true visual hallucinations but did not have delirium at the time.  There are 
many causes of visual hallucinations, other than delirium, and this was not explored.  
Further analysis of the data may explore the impact of factors such as visual 
impairment or medication use.   
The presence or absence of perceptual disturbances was not independently 
associated with mortality, institutionalisation or cognitive decline at follow up.  This 
differs from previous work, which has shown that patients with psychotic symptoms 
and delirium have higher risk of inpatient mortality than those with delirium without 
psychotic symptoms (Paik et al., 2018).  This may be due to a diluting down of the 
impact in DECIDE due to the inclusion of people who did not have delirium and 
experienced only brief episodes of mild perceptual disturbances.  It may suggest that 
perceptual disturbances in isolation are not a marker of poor prognosis in terms of 
mortality, institutionalisation or cognitive decline, although the analysis was not 
powered sufficiently to draw further conclusions.   
These experiences were associated with feeling distressed in nearly half of 
participants and so staff should be encouraged to proactively question patients 
regarding these symptoms.  They can then provide reassurance that they are 
relatively common in people in hospital and, due to the high association with delirium, 
these patients should be screened for delirium. 
7.2.7 Impact on clinical practice 
The DECIDE study provides robust evidence that an episode of delirium significantly 
increases the risk of future dementia, with 31.25% of the participants with delirium 
having a new diagnosis of dementia at follow up as opposed to 3.45% of those 
without delirium during the study.  This information, along with the novel exploratory 
findings from DECIDE regarding the adverse impact of delirium duration, severity and 
multiple episodes of delirium, will support more accurate discussions with patients 
and their relatives regarding prognosis following delirium.  
This data will also provide further evidence that delirium is not a benign and transient 
condition or an inevitability of hospital admission for older people; it is a serious 
condition with significant consequences which needs to be recognised and acted 
upon by all members of the multidisciplinary team. 




Of the 18 participants with a new diagnosis of dementia at follow up, 15 had delirium 
captured by the DECIDE study during the preceding year.  This emphasises the 
importance of asking about a history of delirium when assessing patients for 
dementia in the memory clinic.   
A large proportion of the participants who developed delirium during the study period 
had a history of delirium reported by them or their next of kin.  Previous delirium is a 
recognised risk factor for delirium (Inouye et al., 2014) and this emphasises the 
importance of asking about previous episodes of delirium when risk stratifying 
patients for delirium on admission.   
Given the relationship between delirium and dementia, with each acting as a risk 
factor for the other, it could be argued that delirium should be the red flag for 
dementia that, for example, unexplained weight loss is for cancer.  A patient 
presenting with delirium should initiate an assessment of their baseline cognition, as 
it is possible that they have an undiagnosed dementia.  Patients should also be 
followed up following the resolution of their delirium to complete cognitive testing due 
to their increased risk of developing dementia in the future.  This will facilitate the 
prompt diagnosis and treatment of dementia.  The time period of this follow up review 
is not certain and requires further research, particularly given the challenges of 
persistent delirium and differentiating this from dementia.   
In summary, not recognising and documenting the diagnosis of delirium results in a 
missed opportunity, either to diagnose a pre-existing but undiagnosed dementia, or 
to highlight the patient as high risk for developing future dementia and therefore 
ensuring that they are followed up.  
  




7.3 Strengths and weaknesses 
A major strength of the DECIDE study was the fact that it was nested within an 
existing, well-characterised cohort with known baseline cognition.  The CFAS II study 
is a world renowned cohort which has provided unique dementia prevalence 
estimates (Matthews et al., 2013).  This meant that baseline cognition could be 
robustly accounted for when examining cognitive outcomes after delirium and meant 
that the follow up interviews were standardised and comprehensive.   
A further strength of the DECIDE study were the robust prospective delirium 
assessments using a standardised approach which followed patients longitudinally.  
This has never been done before in the context of an existing cohort study.  
The study recruited to target and consequently, had sufficient power when examining 
cognitive trajectories after delirium.  The confidence intervals when examining 
dementia as a binary outcome are broad, reflecting some uncertainty in the size of 
the risk, probably due to a lack of participants.  The sample size was relatively small 
which limited the exploratory sub group analysis looking into predictors of poor 
outcomes. 
A further strength of the study was that only two people assessed patients in hospital 
and at follow up, one of whom was a trainee in geriatric medicine.  This meant that it 
was easier to ensure inter-rater reliability but meant that participants were seen once 
a day at most, which might not have captured all days with delirium due to the 
fluctuating nature of the condition.  However, the use of notes review and collateral 
history of preceding 24 hours as part of the assessment aimed to capture delirium 
that may not have been present at the time of the prospective assessment.  The 
retrospective reviews (Kuhn et al., 2014) also helped to capture information when 
patients did not want to be seen or were too unwell to be assessed, both practical 
difficulties of real-world research.  These two techniques have not been combined 
before.   
There was very little missing data but if missing data was found, this was closely 
examined.  For example, in the case of the CAMCOG, there was missing data and 
this was found to be not at random.  Having personally carried out the majority of the 
follow up interviews, I was aware of the fact that the follow up interview designed by 
CFAS was long and challenging and would not be possible for those who had more 
severe cognitive impairment.  Therefore, an inability to complete a full CAMCOG was 




often a sign of very severe cognitive impairment.  As such, CAMCOG had a 
significant floor effect which may account for the fact that when used as the primary 
outcome measure of cognition, delirium was not found to be an independent 
predictor whilst it was when MMSE or dementia status were used as primary 
outcome measures. 
It was not possible to define the motor subtype in quite a number of participants.  
This may be because not all delirium affects motor function.  It may also be due to 
the fact that delirium was not prospectively captured but was ascertained through 
notes review or collateral history within 24 hours of the event and participants had 
returned to their normal by the time a full MDAS was recorded.  This has been noted 
previously in a study examining outcomes by motor subtype which found that 13% of 
participants had no motor subtype.  They found that the no-subtype group had a 
better prognosis in terms of mortality, length of stay or institutionalisation (Evensen et 
al., 2019). 
The diagnosis of delirium is often challenging and quite subjective and the 
heterogeneity in previous delirium research is a significant limitation.  The aim of this 
study was to use a standardised approach to delirium ascertainment, which 
combined a number of objective assessments with overall judgement.  However, 
even so, there were cases which were not clear cut when it was not possible to 
definitely say whether delirium was present or absent.  In these situations, a 
consensus panel was used to review all available study data, including from 
retrospective ascertainment, and a decision made as to whether delirium was 
present or absent.  In 4 cases, the two assessors disagreed, and a third assessor 
was brought in to provide a majority decision. The sensitivity analyses that were 
carried out showed that these cases did not impact upon the outcomes of statistical 
analyses.  This robust and transparent approach to delirium ascertainment is 
relatively unique but has been replicated in subsequent research (Davis et al., 2018). 
A limitation of the follow up interviews used by CFAS is that they do not attempt to 
subtype the dementia.  This meant that it was not possible to explore whether 
delirium rates and outcomes differed between different subtypes of dementia.  There 
were also not sufficient numbers within the DECIDE study to perform subgroup 
analyses aiming to explore whether outcomes differed between those with delirium 
alone compared to delirium superimposed on dementia.  These areas may provide 
the focus for future work. 




A further limitation was the variable and considerable time that had elapsed between 
baseline and follow up cognitive assessments, between 3 and 6 years.  The time 
between assessments was included in analysis as a potential confounder to attempt 
to address this.  In order to address the possibility that a participant may have 
developed dementia between their wave II interview for CFAS II and their recruitment 
to DECIDE, sensitivity analysis was performed without the participants who had a 
diagnosis of dementia recorded in their medical records on recruitment to DECIDE 
but did not have a diagnosis at wave II of CFAS II.  This demonstrated that delirium 
remained a strong, independent predictor of new dementia diagnosis.  This was 
reassuring and suggests that this gap between assessments, and any potential 
decline in cognition that had occurred during this time, did not affect the overall 
results.   
Due to the fact that there were only 2 people working on the study, interviewers were 
not blinded to delirium status during hospital admission.  However, the follow up 
interview was objective and standardised and therefore, did not rely on subjective 
assessments of cognition, which may have been affected by knowledge of delirium 
status.  The participants were also followed up a year after their hospital discharges 
and so interviewers had often forgotten the precise details of most hospital 
admissions by this point.    




7.4 Implications for future research 
7.4.1 Delirium: a modifiable risk factor for dementia 
Delirium has been shown to be robustly associated with trajectories of cognitive 
decline.  Therefore, it is reasonable to hypothesise that delirium is a potentially 
modifiable risk factor for dementia. Given that delirium is preventable in around one 
third of cases (Inouye et al., 1999), this paves the way for future dementia prevention 
trials that focus on delirium intervention. Given the current lack of treatments for 
dementia, and the ageing population, prevention is becoming increasingly relevant 
and appealing and may have significant financial implications given the population 
cost of dementia is estimated to be £26 billion (Lewis et al., 2014).  
The next step, having shown this association, is to demonstrate that preventing 
delirium does reduce rates of dementia.  Previous studies exploring strategies for 
delirium prevention have not specifically examined cognitive outcomes.  Delirium 
prevention is complex and although multicomponent interventions have been shown 
to be effective in research studies, their real world utility has not been demonstrated.  
A randomised controlled trial, which aimed to implement a multicomponent 
intervention in a busy acute medical admission system, did not demonstrate an 
impact on health status or service use, but the experience of patients and their carers 
was considerably improved (Goldberg et al., 2013).  As with all multicomponent 
interventions, a further limitation is the fact that it is also not possible to determine the 
effectiveness of individual components.   
Realistically, it may not always be possible to prevent delirium.  An alternative focus 
for future research may be to enhance the recovery from delirium.  Given the 
independent associations demonstrated in DECIDE between delirium, frailty and 
future cognitive decline, this would likely involve both cognitive and physical 
rehabilitation.  This intervention would aim to resolve the delirium as quickly as 
possible and speed up the cognitive recovery with an aim to reduce the number of 
days with delirium and the number of episodes of delirium.  This has not previously 
been examined but is an appealing area for future research and may have huge 
implications for rates of dementia, if shown to prevent cognitive decline, as well as 
lengths of hospital stay, if shown to resolve delirium more quickly.  
There are currently no effective pharmacological interventions to prevent or treat 
delirium and, in fact, many of the medications prescribed can cause significant harm 




(Barbateskovic et al., 2019, Scottish Intercollegiate Guidelines Network, 2019).  Our 
understanding of the pathophysiology of delirium is very limited and good quality 
studies in this area are lacking.  An improved understanding of the fundamental 
physiology underlying delirium may provide targets for potential interventions 
including pharmacological treatments.      
7.4.2 Follow up after delirium 
There is a need for further research into the follow up of patients after delirium.  
Firstly, the DECIDE study has shown that these people are at high risk of dementia 
and so by following people up routinely following delirium, it may be possible to 
expedite a diagnosis of dementia and facilitate earlier treatment.  However, the ideal 
time period before follow up is not known and is complicated by the fact that delirium 
can persist for several months.  Therefore, it may be beneficial to leave a longer 
period between discharges and follow up.  However, as demonstrated by DECIDE, 
these people are at high risk of further delirium and hospital admissions and may 
never experience a longer period free from admission to hospital.    
The content of this follow up also requires further research.  Simply limiting it to a 
cognitive assessment may miss the opportunity to address some of the longer-term 
psychological sequelae associated with delirium.  This may also be an opportune 
time to address other risk factors for dementia such as hypertension, smoking status 
and hyperlipidaemia.     
7.4.3 Outcome measure selection 
The DECIDE study emphasises the importance of selecting an appropriate outcome 
measure which thoroughly assesses multiple cognitive domains but remains 
achievable for people with a range of cognitive deficits.  In the DECIDE study, 
despite the significant associations demonstrated between delirium and MMSE and 
delirium and dementia diagnosis, this was not replicated when CAMCOG was the 
primary outcome measure.  This may be due to the missing data which exists when 
participants are unable to complete the CAMCOG, which occurred in 18 of the 135 
participants followed up at 1 year.  This is missing not at random and, in the DECIDE 
study, was due to participants being too cognitively impaired to complete the full 
assessment (13 participants) or due to poor hearing or vision (3 participants).  The 
CAMCOG is a comprehensive assessment of cognition, which takes around 20-30 
minutes to complete (Huppert et al., 1995).  Although CAMCOG provides lots of 
detailed information about cognitive domains as well as being a sensitive measure of 




cognition which avoids the ceiling effects of the MMSE (Huppert et al., 1995), it is 
susceptible to the floor effect associated with severe cognitive impairment.  In the 
original study, 33 of 451 participants were unable to complete the CAMCOG due to 
cognitive impairment (Huppert et al., 1995).  Therefore, CAMCOG score may not be 
an appropriate outcome measure in a cohort in which significant cognitive impairment 
may exist.  In the DECIDE study, MMSE was found to be more inclusive as an 
outcome measure as only 3 people were too cognitively impaired to complete it.  
However, it lacks the sensitivity of the CAMCOG to subtle declines in cognition and is 
known to be confounded by levels of education and cultural norms (Devenney and 
Hodges, 2017). 
Using a diagnosis of dementia as a binary outcome measure avoids the problems of 
missing data associated with using CAMCOG.  However, such a binary outcome 
does not provide more nuanced information regarding cognitive domains specifically 
and also considerably reduces the power of the data, perhaps resulting in large 
confidence intervals. There were very few people who had a new diagnosis of 
dementia at follow up interview who had not had delirium during the study period (3 
people).  The small number of people in this category probably also contributes to the 
large confidence intervals seen in DECIDE.   
Using a measure of cognition alone as an outcome measure results in significant 
survival bias as participants had to survive to a year after their hospital admissions in 
order to complete their follow up assessments.  Delirium is associated with a 
significantly increased risk of death and mortality varied significantly between those 
who did and did not have delirium.  Therefore, examining poor outcome as a whole, 
including death, dementia and institutionalisation, is more inclusive and avoids this 
survival bias.  This survival bias may explain why delirium was not an independent 
predictor of new care home admission: it is possible that the people with delirium did 
not live long enough to move into a care home.  
7.4.4 The involvement of older people in research 
The DECIDE study demonstrates that older people are keen to take part in research, 
even when admitted to hospital and acutely unwell.  The recruitment rate was 73.2% 
and the follow up rate was 80.8% (135/167), when removing those who had died.  
This should support the argument against the exclusion of older people from many 
research studies, including those with dementia.   




7.4.5 Further analysis of the DECIDE cohort 
The DECIDE cohort is a highly valuable resource and unique cohort.  Although the 
primary aim of the study was to explore cognitive outcomes after delirium, it is 
appealing to use the data to investigate other hypotheses surrounding 
hospitalisation, delirium and dementia in older people:   
• Physical function as a surrogate marker of delirium status 
A novel measure of physical function, the Hierarchical Assessment of Balance And 
Mobility (MacKnight and Rockwood, 2000), was recorded each time participants were 
assessed.  Within the scope of this project, there has not been time to investigate 
how this fluctuated with the presence or absence of delirium or whether this impacted 
on outcomes.  It has been hypothesised that physical functioning may be a good 
surrogate marker of delirium status (Gual et al., 2018) but this has not been tracked 
longitudinally.   
• Confounding effects of visual and hearing impairment 
A further hypothesis which can be explored using the cohort is the possible 
confounding effect of visual and hearing impairment on the development of dementia 
following delirium, both of which were measured objectively as part of the CFAS 
interview at baseline and follow-up. 
• Elective versus emergency hospital admission 
It will be possible to compare the rates of delirium and risk of adverse outcomes in 
those with an elective as opposed to an emergency hospital admission. 
• Prevalent versus incident delirium 
No attempt was made in the analysis to differentiate between prevalent (present on 
admission to hospital) and incident (occurring during admission) delirium due to the 
small subgroups this would have created.  No previous population-based studies 
have been able to explore the impact on outcomes of these differing diagnoses due 
to the retrospective nature of their delirium ascertainment (Davis et al., 2013).  Due to 
the longitudinal nature of DECIDE, following participants throughout their 
hospitalisations over the study period of one year, it is possible to ascertain whether 
each case of delirium was prevalent or incident and explore whether these resulted in 
differing outcomes.  




• Modelling delirium longitudinally 
DECIDE also provides a unique opportunity to model delirium longitudinally in a 
population-based study using repeated measures analysis.   
• Cognitive trajectories 
Due to the fact that 3 measures of cognition are available for the cohort, two from 
CFAS II and one from DECIDE, it will also be possible to explore the impact of 
delirium on the rate of cognitive change measured using the MMSE. 
 
  




7.6 Case study continued 
…“Will she get dementia?”  
The doctor takes a deep breath, and then replies: 
“Research shows that older people who get delirium whilst in hospital have a higher 
risk of getting dementia in the future.  However, most people will recover well from 
their delirium and not develop dementia.  We know that the risks of developing 
dementia after having delirium are higher in people who have delirium more than 
once, people who have more than 5 days of delirium and people who have more 
severe delirium.” 
 





An episode of delirium whilst an inpatient in hospital significantly increases your risk 
of future cognitive decline and new dementia, independent of illness severity and 
baseline cognition.  This has been robustly shown for the first time in a population-
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Data collection forms 
1. Demographics and Admission Information 
2. Daily Review 





Form completed by? □ (please initial) 
Date: _________________ 
Data entered onto database □ 
Demographics and Admission Information  
Version 1.1 18/12/15 
Entered onto database? □ (please initial) 
Date: _________________ Demographics 
Unique Study Identifier   
Age   
Gender   



























































History of depression? Yes / No     History of metastatic disease? Yes / No 
History of delirium from clinical 
records? 
Yes / No     History of haematological malignancy? Yes / No 
History of delirium from patient 
or their informant? 




Demographics and Admission Information  
Version 1.1 18/12/15 
Admission Information 
Unique Study Identifier 
 
   
Admission date 
 
 Visual Impairment? 
 
Yes / No 
Previous wards 
 
 Hearing Impairment? 
 
Yes / No 
Weight (kg) 
 





 Care package  
MUST score 
 





Yes / No Elective surgery? 
 
Yes / No 
4AT completed in 
clerking booklet? 
 
Yes / No Catheter in situ prior to 
admission? 
 
Yes / No 
Immunocompromised? 
 
































   
Admission diagnosis 
 




The Barthel Index 
Bowels  
0 = incontinent (or needs to be given enemata)  
1 = occasional accident (once/week)  
2 = continent  
  
Bladder  
0 = incontinent, or catheterized and unable to manage  
1 = occasional accident (max. once per 24 hours)  
2 = continent (for over 7 days)  
  
Grooming  
0 = needs help with personal care  
1 = independent face/hair/teeth/shaving (implements provided)  
  
Toilet use  
0 = dependent  
1 = needs some help, but can do something alone  
2 = independent (on and off, dressing, wiping)  
  
Feeding  
0 = unable  
1 = needs help cutting, spreading butter, etc.  
2 = independent (food provided within reach)  
  
Transfer  
0 = unable – no sitting balance  
1 = major help (one or two people, physical), can sit  
2 = minor help (verbal or physical)  
3 = independent  
  
Mobility  
0 = immobile  
1 = wheelchair independent, including corners, etc.  
2 = walks with help of one person (verbal or physical)  
3 = independent (but may use any aid, e.g., stick)  
  
Dressing  
0 = dependent  
1 = needs help, but can do about half unaided  
2 = independent (including buttons, zips, laces, etc.)  
  
Stairs  
0 = unable  
1 = needs help (verbal, physical, carrying aid)  
2 = independent up and down  
  
Bathing  
0 = dependent  









Version 1.1 18/12/15 
Form completed by? □ (please initial) 
Date: _________________ 
Entered onto database? □ (please initial) 
Date: _________________ Daily review 
Part 1: From the medical records 
Unique study identifier  Participant willing to be assessed? Yes / No 
Admission Date  Date of assessment  
Place of assessment  Time of assessment  
From file at end of bed:    
NEWS score  AVPU  
Temperature  Pain score  
Blood pressure  Last bowels open when?  
Heart rate  Urinary catheter in situ? Yes / No 
Respiratory rate  FOCUS chart completed? Yes / No 
Saturations  Mechanically ventilated? Yes / No 
Inspired oxygen (“0” if not on oxygen)  CPAP? Yes / No 
Any emergency surgery? Yes/No Fluid chart completed?  
(if yes, document input) 
Yes/No 
Forget Me Not completed? Yes/No Food chart completed? Yes/No 
From e-record:    
Haemoglobin  Urea  
Haematocrit  Creatinine  
White blood cells  CRP  
Platelets  Albumin  
Fibrinogen  Lipids  
Sodium  Glucose  
Potassium  Vitamin D  
Bicarbonate  Adjusted calcium  
Any medication changes? 
 
From clinical notes:    




 Daily review 
Version 1.1 18/12/15 
Part 2: Semi-structured interview 
Hello. 
My name is ……………………………………. and I am a doctor/nurse carrying out a research project about 
older people in hospital.   
Do you remember me? 
Would it be OK to have a chat with you now? 
How are you today? 
Tell me what’s been happening since I last saw you? 
Are you feeling muddled at all? 
Have you been getting along with the nurses +/- family OK? 
One orientation question (Where are we now? / Do you know what day of the week it is? / Do you know what 
month it is? / Do you know what year it is? ) 
Sometimes when people are in hospital, they can see or hear things that are not there or that seem strange.  
Do you think you have experienced this? 
Vigilance test – tapping for letter A in string of letters 
Roughly what time of day is it at the moment? 
 
Score using the modified Delirium Observation Screening Scale: 
□ Dozes off during conversation or activities 
□ Is easy distracted by stimuli from the environment 
□ Does not maintain attention to conversation or action 
□ Does not finish question or answer 
□ Gives answers that do not fit the question 
□ Reacts slowly to instructions  
□ Thinks they are somewhere else 
□ Does not know which part of the day it is 
□ Does not remember recent events 
□ Is picking, disorderly, restless 
□ Pulls cannulas, feeding tubes, catheters etc. 
□ Is emotionally labile 
□ Sees/hears things which are not there 
 
□ IN PEOPLE WITHOUT DEMENTIA, IF ANY OF THE ABOVE ARE ABNORMAL, CONTINUE TO 
FULL MDAS. 
 
□ IN PEOPLE WITH DEMENTIA, CONTINUE TO MDAS IF THERE HAS BEEN AN ACUTE CHANGE 
OR IF ANY OF THE ABOVE ARE ABNORMAL EXCEPT: 
o Thinks they are somewhere else 
o Does not know which part of the day it is 
o Does not remember recent events 
 







Version 1.1 18/12/15 
Part 3: Ask the participant:  
1. What day of the week is it?  
2. What month are we in?  
3. What year is it?  
4. What is the date today?  
5. Which hospital is this?  
6. Which floor are we on?  
7. What season is it?  
8. Which city are we in?  
9. Which country are we in?  
10. What time is it?  
What year did World War II end?  
Will a stone float on water?  
Listen and repeat these three words:  
(choose one set) 
 
• Lemon – Key – Ball 
• Table – Apple – Cigar 
• Sky – Penny – Duck 
Document number repeated and then instruct to 
remember all three words 
Listen to the following numbers.  I’d like you to 
repeat them in the order I say them: 
 
(start with 3 numbers and if correct, then 4 
numbers and if correct then 5 numbers – move 
on only if answers correctly) 
 







Listen to the following numbers.  I’d like you to 
repeat them backwards, in reverse order to how 
I say them. 
• 7-5-2 
• 4-9-0-7 
Document number repeated backwards (0, 3 or 4) 
Can you tell me the months of the year, from 
January to December, but in reverse order, 
starting from December and finishing with 
January? 
Month reached: D  N  O  S  A  J  J  M  A  M  F  J 
≥7 correct 
Starts but scores <7 OR refuses to start 
Untestable 
Name this object (hold up pen).  What is it used 
for? 
 
Take this pen in your right hand and use it to 




 Daily review 
Version 1.1 18/12/15 
 
GCS: 
Eye opening:  ________ / 4 
Voice:  ________ / 5 
Movement: ________ / 6 
What were the 3 objects that I asked you to 
remember? 
 
Have you been sleeping well? Yes / No 
 
Have you been bothered by any vivid dreams?  
Have any dreams seemed to continue while 
you’ve been awake?  
 
Have you seen anything unusual?  What do you 
think it was? 
 
Have you seen or heard anything you think 
shouldn’t be there? 
 
Sometimes people in hospital have quite odd 
thoughts.  Have you noticed anything? 
 
How have you been getting on with staff, family 
and friends? 
 
Have you felt distressed at all? 
 
 
MDAS items:  
Perceptual Disturbance  
Delusions  
Ability to shift and maintain attention  
Disorganised thinking  
Part 4: Ask the informant (relative/friend/nurse): 
Collateral history from?  
 




Do you think they have been more confused 
lately? 
Yes / No 
 
Are they the same every time you see them? 
(fluctuations) 
Yes / No 
 
Have they been wandering? Yes / No 
 
Do they seem to get lost on the ward? Yes / No 
 
How have they been sleeping?  
 
Open visiting? Yes / No 
 
Summary of informant history:  
Onset No significant change from usual 
Gradual onset - several weeks to a month 
Acute change occurring over days to a week 
Abrupt change over several hours to a day 
Fluctuations  
Sleep-wake cycle disturbance  
Part 5: General observations:  
Hearing aids in place? Yes / No / N/A 
Glasses in place? Yes / No / N/A 











Version 1.1 18/12/15 
m-RASS: 
 
Level of consciousness (from MDAS):  _________________ 
Psychomotor activity (from MDAS): _________________ (including letter) 
HABAM: (please mark with a cross the most appropriate for each of the three modalities): 
BALANCE  TRANSFERS  MOBILITY  
Stable ambulation  Independent  Unlimited  
Stable dynamic standing  1 person standby  Limited to >50 m  
Stable static standing  1 person minimal assist  Unlimited with aid  
Stable dynamic sitting  1 person assist  With aid >50m  
Stable static sitting  2 person assist  With aid 8-50m  
Impaired static sitting  Total lift  1 person standby/ +/- aid  
 




1 person hands-on/ +/- 
aid 
 
Lying to sitting 
independently 
 
Positions self in bed  





1 year follow up additional questions 
 
REM sleep disorder 
Ask:  
“Does [xxx] ever wake up in the night thrashing about or acting out their dreams?” 
 
Identifying episodes of delirium  
Read:  
“This section is designed to ask about symptoms or behaviours that may suggest that [xxx] had an episode of 
delirium.  Your observations of these behaviours can be very helpful in identifying delirium.  We are looking for 
any changes in behaviour that happened quite quickly (days to weeks) and lasted for just a short time (days to 
weeks).  If you can remember when this episode happened (which month), this would also be very useful. 
 
Sometimes, several behavioural observations are mentioned in a single question.  The answer should be ‘yes’ 
if any one of these observations were present.” 
 
Ask:  
“Over the past year, score yes if you have noticed any of the following which lasted for a few days to weeks 
and state roughly when this occurred:” 
 
Description of behaviour Present? 
(please circle) 
When? 
I did not recognise him/her as their usual self  Yes/No  
I often had to repeat things to get his/her attention  Yes/No  
He/she was less alert and/or appeared to be drowsy 
during the daytime  
Yes/No  
He/she had little spontaneous movement and hardly 
moved their arms  
Yes/No  
He/she was often awake at night and sleepy during the 
day  
Yes/No  
He/she had recently become more forgetful  Yes/No  
When the conversation stopped, his/her eyes closed  Yes/No  
He/she was difficult to awaken  Yes/No  
He/she was combative and struggled to get free  Yes/No  
He/she said strange things that didn’t make any sense Yes/No  
 
Ask and document free text: 
“At the time of the above symptoms, was [xxx] unwell at all?  Did they have to see a doctor?  What was wrong 
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